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ABSTRACT 
Insulin resistance and abnormal insulin secretion are central to type 2 diabetes. The 
relationships have been established between lipid accumulation in the liver and muscle 
and insulin resistance, and that of lipid accumulation in the pancreas and β cell 
dysfunction. Therefore it is vital to assess the effect of therapies on intra-organ lipid 
concentration.  
DPP-4 inhibitor vildagliptin is a new therapeutic agent in type 2 diabetes. Its known 
primary mechanism of action is to delay GLP-1 and GIP degradation, and enhance 
their endogenous concentration. GLP-1 and GIP increase the sensitivity of the α- and 
β-cells to glucose concentration. Although DPP-4 inhibitors have been found to 
decrease postprandial triglyceride levels and lipolysis, the effect on intra-organ lipid 
concentration is unknown. 
Glycogen storage in the liver and muscle in type 2 diabetes is subnormal, nonetheless, 
the extent of glycogen storage abnormality after a whole day of normal eating has not 
been previously examined. 
Although abnormal β cell function has been recognised as a feature of type 2 diabetes, 
the whole pancreas has not been extensively studied previously. 
To test the hypothesis that DPP-4 inhibitors modulate intra-organ lipid accumulation, 
44 well-controlled type 2 diabetes subjects treated only with metformin were 
randomised in a double-blinded manner to receive either vildagliptin or placebo for 6 
months. In order to assess the extent of change, in intra-organ lipid content, and 
abnormal glycogen storage, and to provide comparative data for pancreas 
morphology, 14 normal glucose tolerant subjects matched for weight, BMI, sex and 
age were studied.  
A clinically significant decrease in liver triglyceride content after 6 months treatment 
with vildagliptin was observed. Additionally, the studies demonstrate that the pancreas 
volume in type 2 diabetes was smaller compared to match controls, and that muscle 
did not contribute to glycogen storage during normal daily eating in type 2 diabetes. 
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CHAPTER 1 INTRODUCTION 
1.1 Natural history of type 2 diabetes 
Although diabetes mellitus was first recognised as a disease more than 3500 years 
ago, understanding its pathology and development in managing the disease have been 
revolutionised only in the last century. The great Greek physician Aretaeus was 
amongst the first to document polyuria as a symptom of diabetes mellitus (30 - 90 CE). 
The term diabetes is translated from the Greek for a siphon–rapid passage of fluid out 
and in; mellitus refers to the sweet taste of urine. Much later (980 - 1037) the Persian 
physician Aricenna gave a more detailed description of symptoms such as sweet taste 
in a diabetic urine, abnormal appetite and loss of sexual function. Although Von Mering 
and Minkowski first described the role of the pancreas in normal glucose metabolism 
in 1889 (Von Mering, 1890), Banting and Best were the first to purify insulin for clinical 
use. The latter was an important milestone in developing the treatment for diabetes. 
It was initially believed that only one form of the disease existed and this was due to 
insulin deficiency. However, the distinction between insulin dependent (type 1) and 
non-insulin dependent diabetes (type 2) was first recognised as far back as 400 - 500 
CE by Indian physicians Sushrata and Charaka. The distinction between both types 
was demonstrated and documented by Harold Percival Himsworth in 1936 using oral 
glucose tolerance tests with or without injected insulin (Himsworth, 1936). The 
development of radioimmunoassay to measure endogenous insulin concentration by 
Yalow and Berson (Yalow and Berson, 1960) allowed characterisation of 
hyperinsulinaemia, a marker of insulin resistance in non-insulin dependent (type 2) 
diabetes. The United Kingdom Prospective Diabetes Study (UKPDS) gave further 
insight into the pathophysiology of type 2 diabetes. Firstly, it was recognised that blood 
glucose increased with the duration of type 2 diabetes in the tight glycaemic control 
group; and secondly, fasting hyperinsulinaemia was a distinctive feature in the type 2 
diabetes (UKPDS, 1999). This allowed the description of insulin resistance as the 
earliest detectable abnormality, and insulin secretory defect as a later abnormality in 
type 2 diabetes (Taylor, 2013). 
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1.2 New insights in the aetiopathophysiology of type 2 diabetes 
Insulin resistance and subnormal glucose stimulated insulin secretion underpin the 
aetiopathophysiology of type 2 diabetes. Previously, it was thought that these two 
processes were inevitably progressive; and multiple oral agents and insulin therapy 
would be required to maintain normal glucose control as type 2 diabetes progressed. 
Recent work contributing to better understanding of the disease, has led to the 
development of interventions which can cause disease remission or in some cases 
retard progression (Pories et al., 1992; Dixon et al., 2008; Lim et al., 2011a). 
Therapeutic interventions such as bariatric surgery and very low calorie diet have 
proved efficient in disease remission; while incretin based therapies with GLP-1 
agonists have been shown to improve glycaemic control without weight gain.  
It is now known that insulin resistance is present well before the diagnosis of type 2 
diabetes is confirmed (Ferrannini et al., 2004), but plasma glucose rises considerably 
only when pancreatic β cells fail to secrete insulin in response to nutrient (Cali et al., 
2009). This suggests that the onset of insulin resistance and β cell dysfunction differ 
and the two concepts should be considered separately. Although muscle insulin 
resistance is commonly present in type 2 diabetes, it does not fully explain the entire 
pathophysiological process of type 2 diabetes. If muscle insulin resistance is solely 
accountable, it would be expected that all individuals with muscle insulin resistance 
would develop type 2 diabetes, however this is not the case (Taylor, 2012). 
Additionally, early normalization of plasma glucose achieved by improving hepatic 
insulin sensitivity and not muscle insulin sensitivity (Lim et al., 2011a)  suggested that 
liver insulin sensitivity plays a very important role in the development of type 2 diabetes, 
irrespective of the presence of muscle insulin resistance.  
Over time, β cell mass decreases and about 50% is present at the time of diagnosis 
(Butler et al., 2003). However, there is growing evidence to suggest a common 
aetiology to both β cell dysfunction and insulin resistance in liver and muscle. Abnormal 
lipid accumulation in the pancreas, liver and muscle has been implicated in β cell 
dysfunction and insulin resistance respectively. Although individual genetic 
predisposition has to be present for the development of type 2 diabetes, chronic calorie 
surfeit is crucial to lipid accumulation in all three organs.
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1.2.1 Insulin resistance in muscle 
Muscle insulin resistance has been recognised to be active at the early stages of 
metabolic syndrome and onset of type 2 diabetes (Petersen et al., 2007). After a meal, 
insulin-stimulated glucose uptake by the muscle is impaired and glycogen storage is 
negligible (Carey et al., 2003). In order to prevent postprandial hyperglycaemia 
resulting from muscle insulin resistance, there is an initial physiological response to 
increase basal insulin secretion. If excess calorie intake continues, basal 
hyperinsulinaemia is exacerbated and normal or near-normal plasma glucose 
concentration is initially maintained. Nevertheless, chronic basal hyperinsulinaemia 
causes persistently high insulin concentration in the portal circulation, which enhances 
de novo hepatic lipogenesis and predisposes to increased liver fat synthesis and 
storage. 
The inability of insulin resistant individuals to store glucose in the muscle has been 
reported to be associated with defects in insulin signalling, glucose transport receptors, 
glucose phosphorylation, and a reduction in glucose oxidation and glycogen synthesis 
(Bajaj and Defronzo, 2003; Bouzakri et al., 2005; Karlsson and Zierath, 2007). Even 
though a mitochondrial defect was thought to account for muscle insulin resistance in 
type 2 diabetes (Petersen et al., 2004), present evidence suggests that primary 
mitochondrial function is not defective in muscle insulin resistance (Schrauwen-
Hinderling et al., 2007). However it is suggested that secondary mitochondrial defect 
from hyperglycaemia and muscle lipid accumulation may potentially play a role (Lim et 
al., 2011b; Lim et al., 2011c). 
 
 
1.2.2 Insulin resistance in liver 
There is growing evidence to suggest that liver fat accumulation is an important 
contributing factor to the aetiology and pathogenesis in type 2 diabetes. Not only has 
the incidence of type 2 diabetes been shown to be higher in individuals with fatty liver 
(Shibata et al., 2007), but also the association between hepatic insulin resistance and 
lipid accumulation has been amply demonstrated (Seppala-Lindroos et al., 2002; 
Petersen et al., 2007; Ravikumar et al., 2008; Lim et al., 2011a). In type 2 diabetes, 
fatty liver has been found to be associated with the failure to suppress hepatic glucose 
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production, an indicator of hepatic insulin resistance (Petersen et al., 2007; Ravikumar 
et al., 2008).  
The supply of fatty acid to the hepatocyte can be from two main sources: 
extracellularly, the uptake of NEFA and LDL; and intracellularly, de novo lipogenesis 
and the breakdown from intracellular triacylglycerol and diacylglycerol stores. The fate 
of intracellular fatty acid is crucial to intra-hepatic triglyceride accumulation and needs 
to be considered. Intra-hepatic lipids can either be safely stored as triacylglycerol, 
metabolised in the mitochondria for energy, or exported as VLDL-triacylglycerol to 
other organs. Mitochondrial oxidation of fatty acid is reduced in type 2 diabetes. In well 
controlled type 2 diabetes subjects (HbA1c 7.1±1.0%), a 25% reduction in hepatic 
mitochondrial oxidation of fatty acid has been reported when compared to age, sex 
and BMI matched controls (Szendroedi et al., 2009). Considering that the study group 
were well controlled type 2 diabetes subjects, it is likely that the defect in mitochondrial 
lipid oxidation is present before the diagnosis of type 2 diabetes.  As mitochondrial fatty 
acid oxidation is suppressed, intracellular concentration of diacylglycerol and fatty 
acids rises (Kumashiro et al., 2011). The accumulation of diacylglycerol activates 
protein kinase C (PKCε), which in turn prevents the intra-hepatic transport protein 
insulin receptor substrate 1 (IRS1) from binding to the transmembrane insulin receptor 
(Samuel et al., 2010). Additionally, excess fatty acids in the hepatocyte promote the 
synthesis of ceramide, which is thought to play a role in the deactivation of Akt, thus 
affecting the insulin-signalling pathway (Kumashiro et al., 2011) Figure 1.1. 
In a small proportion of individuals with non-alcoholic fatty liver disease (NAFLD) who 
were found to have a G allele mutation of the PNPLA3 or rs738409 gene, insulin 
sensitivity was found to be normal (Speliotes et al., 2010). PNPLA3 is a patatin-like 
phospholipase or adiponutrin gene expressed in adipose tissue, and functions as a 
lipase for hydrolysis of triacylglycerol. Expression of the mutant gene prevents the 
breakdown of triacylglycerol and allows safe storage within the hepatocyte. As such 
the accumulation of diacylglycerol and fatty acid is prevented and insulin signalling is 
preserved. 
The accumulation of lipids in the liver causes metabolic strain on the hepatocytes, 
which results in a rise in alanine transaminase (ALT) (Sevastianova et al., 2012). ALT, 
an enzyme present in high concentration within hepatocytes is released into plasma 
after stress or injury to the hepatocyte. Therefore it can be considered as a marker of 
hepatocyte health. 
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As such, a rise in ALT can be considered as a clinical surrogate marker for fatty liver 
and an indicator for insulin resistance in the liver in most individuals without the G allele 
of PNPLA3 (Tushuizen et al., 2006).  
 
 
 
Figure 1.1 Intrahepatic activity of fatty acid 
 
 
1.2.3 Pancreas dysfunction in type 2 diabetes 
The β cells of the pancreas have a supple but precise characteristic that enables 
normal blood glucose concentrations to be maintained. They are nutrient sensing cells, 
which respond to the presence of nutrient by insulin biosynthesis and secretion. 
Adenosine triphosphate (ATP) produced from glucose metabolism is required for 
exocytosis of insulin. However intra-pancreatic fatty acid is likely to impair ATP 
production by inhibiting pyruvate dehydrogenase (Zhou et al., 1996), and as such 
glucose stimulated insulin secretion is impaired. During chronic excess calorie surfeit, 
lipids are predominantly exported to the pancreas from the liver as VLDL-TG. The 
uptake of fatty acid by the β cells is mediated through an integral CD36 membrane 
protein (Noushmehr et al., 2005).  
When β cells are cultured in vitro in very low concentration of fatty acid (0.33mmol// 
palmitate) for 48 hours, they avidly take up fatty acid and decrease glucose stimulated 
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insulin secretion (Lalloyer et al., 2006). It is now known that lipid accumulates in the β 
cells of the pancreas (Pinnick et al., 2008). Very little is known about the effect of 
pancreatic lipid accumulation on α cells. However, in type 2 diabetes the inverse 
relationship between insulin and glucagon secretion is lost and glucagon concentration 
is inappropriately high. This suggests that abnormal α cell function is likely to be 
secondary to β cell dysfunction which is associated with pancreatic lipid accumulation. 
Rodent studies have provided robust evidence for the differentiation of the β cells to 
glucagon-secreting ‘α - like’ cells in response to hyperglycaemia, providing a unifying 
explanation for the complementary twin hormone abnormalities seen in type 2 diabetes 
(Talchai et al., 2012; Brereton et al., 2014). 
The association between pancreatic lipid accumulation and β cells dysfunction has 
been recognised for some time. When in vitro β cells are incubated in 2mmol/l fatty 
acid for 48 hours, intra-pancreatic fatty acid content rise by 65% (Lupi et al., 2002b). 
Additionally, in vivo studies demonstrated that  the pancreatic triglyceride content in 
type 2 diabetes subjects was associated with a blunted acute phase β cells response 
to nutrient (Tushuizen et al., 2007; Lim et al., 2011a). In the latter study, the first phase 
insulin response gradually normalised over 8 weeks of 600kcal diet as pancreas 
triglyceride reduced to levels comparable with matched controls.  
Additionally, the accumulation of fatty acid in the pancreas inhibits β cells proliferation 
and promotes apoptosis. The inhibition of β cells proliferation is mediated through the 
stimulation of p16 and p18 cell cycle inhibitors (Pascoe et al., 2012). Cadaveric 
examination of the pancreas revealed a 50% reduction in β cells; the mechanism for β 
cell loss was thought to be due to an increased rate in apoptosis (Butler et al., 2003).  
The association between lipid accumulation in the β cells and increased rate of 
apoptosis has been previously described (Shimabukuro et al., 1998a). 
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1.3 Incretin hormone biology  
1.3.1 Background to incretin hormones 
As early as 1906, hormones produced by the intestine were thought to have an effect 
on insulin secretion. McIntyre et al were able to prove that oral glucose induced a larger 
insulin secretory response when compared with a similar intravenous glucose 
concentration (McIntyre et al., 1964). This led to a new concept called the incretin 
effect, which is defined as the difference in β cell insulin secretory response to equal 
moles of glucose administered either orally or intravenously (Rehfeld, 2011). The 
incretin effect has been reported to account for 50 - 70% of the total insulin secreted 
after a meal (Baggio and Drucker, 2007).  
 
 
1.3.2 Secretion and metabolism of incretin hormones 
The two main hormones contributing to the incretin effect are Glucagon-Like Peptide 
1 (GLP-1) and Glucose-Dependent Insulinotropic Polypeptide (GIP).  Incretin 
hormones are released autonomously from the entero-endocrine cells of 
gastrointestinal tract in response to nutrient absorption. Plasma concentration start to 
rise within 10 - 15 minutes of oral glucose ingestion, reaching a peak at 2 hours, and 
slowly decline thereafter. They enhance meal stimulated insulin secretion, through a 
neuro-endocrine pathway (Ahren and Holst, 2001; Drucker and Nauck, 2006).  
Dipeptidyl peptidase-4 (DPP-4) enzyme inactivates and degrades incretin hormones 
by splitting the di-peptide bond from the N terminus (Deacon et al., 1995). The enzyme 
is soluble in plasma and widely distributed in various tissues. As a result of rapid local 
and peripheral inactivation, only 10 - 15 % of intact GLP-1 reaches the pancreas 
(Deacon et al., 1995) Figure 1.2. This suggests that part of their effect may be mediated 
through the local afferent intestine neurons or through the portal vein. Sympathetic 
nervous system activation by DDP-4 inhibition has been shown to be associated with 
postprandial lipid mobilization and oxidation (Boschmann et al., 2009). The inhibition 
of DDP-4 increases endogenous GLP-1 and GIP concentration and thus potentiates 
the physiological effect of intact incretin hormones on insulin secretion, resulting in an 
improvement in glycaemic control. Consequently, DDP-4 inhibitors are now 
established as a treatment option in type 2 diabetes. 
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Figure 1.2 Secretion and metabolism of GLP-1 (Deacon et al., 1995)  
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1.3.3 Glucagon-Like Peptide 1 (GLP-1) 
GLP-1 is a pro-glucagon derived peptide (PGDP) derived from the main precursor pro-
glucagon (Baggio and Drucker, 2007), which is a product of the glucagon gene 
translation (Carson et al., 1983). The glucagon gene is expressed on α cell of the 
pancreas and the neuro-endocrine L cells of the distal intestine (Mojsov et al., 1986). 
GLP-1 is secreted from the L cells of the distal intestine in response to nutrient 
absorption (Eissele et al., 1992). The most important nutrients stimulating GLP-1 
release are glucose and triacylglycerol (TAG) (Orskov et al., 1991). Neurotransmitters 
and peptide such as acetylcholine and gastrin-releasing peptide may contribute to the 
pulsatile GLP-1 secretion (Herrmann-Rinke et al., 1995; Balks et al., 1997; Rocca and 
Brubaker, 1999). The rapid rise in GLP-1 immediately after a meal may suggest that 
the secretion of the incretin hormones is partially mediated by neurotransmitters and 
neuro-peptides (Ahren and Holst, 2001; Nauck et al., 2011).  The proximal intestine 
may also contribute to GLP-1 release through the neuro-endocrine pathway. Intact 
GLP-1 diffuses across the basal membrane and lamina propia. On entering the 
capillaries of the intestine, GLP-1 is rapidly degraded by DPP-4 enzyme, which lines 
the endothelial cells (Staehr et al., 2001). 
 
 
1.3.4 L cells 
The L cells are predominantly found in the distal colon (Eissele et al., 1992), but they 
have also been located in the lamina propia of the villi lining the small intestines. They 
have G-protein coupled receptors, which are specific for different substrates (Brubaker, 
2010). The following receptors of the L cells have been identified and described: 
 Sweet taste and G-protein (gustducin) receptor: specific for glucose (Jang et 
al., 2007). 
 NEFA or G protein receptor (GPR) 119: specific for long chain monosaturated 
NEFA (Lauffer et al., 2009). 
 GPR40 receptor: specific for long chain saturated fatty acids (Hirasawa et al., 
2005; Zhao et al., 2008). 
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 GPR120 receptor: specific for long chain polyunsaturated fatty acids 
(Hirasawa et al., 2005; Edfalk et al., 2008). 
 GPR131 or TGR 5-GPR131 receptor: specific for bile acids (Evans et al., 
2009). 
The first four receptors are likely to be directly involved in the stimulation of incretin 
secretion. 
 
 
1.3.5 Glucose-Dependent Insulinotropic Polypeptide (GIP) 
GIP is a 42 amino-acid peptide (Holst and Orskov, 2004), derived from the glucagon-
secretin group of peptide (Takeda et al., 1987). It is predominantly secreted from the 
K-cells in the duodenum and jejunum (Mortensen et al., 2000; Baggio and Drucker, 
2007). The most important stimulant of GIP secretion is dietary lipid, but carbohydrates 
also contribute significantly (Baggio and Drucker, 2007). A 10 - 20 fold increase in GIP 
secretion in response to a meal has been documented (Holst and Orskov, 2004). The 
half-life of GIP in normal subjects is about 7 minutes but it is reduced to 5 minutes in 
patients with type 2 diabetes (Deacon et al., 2000). 
 
 
1.3.6 Incretin hormone receptors 
Incretin hormones exert their effect by interacting with receptors which are widely 
distributed in various organs. The GLP-1 receptor can be found on α, β, and δ cells of 
the pancreas, the central and peripheral nervous system, the lung, the heart, and the 
gastrointestinal tract (Drucker and Nauck, 2006; Baggio and Drucker, 2007).  Although 
the role of GLP-1 receptors in adipose tissue has been poorly documented, it has 
recently been suggested that GLP-1 receptor is over- expression in obesity (Vendrell 
et al., 2011).  
The GIP receptor is a transmembrane G-protein predominantly found on β cells of the 
pancreas, stomach, small intestines, pituitary and adrenal gland, vascular 
endothelium, bone, central nervous system and adipocytes (Usdin et al., 1993; Yip et 
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al., 1998; Basu et al., 2003; Drucker and Nauck, 2006). After ingestion of a meal, 
release of incretin hormones occurs and these are transported in plasma to the 
pancreas. They interact with the receptors on the β cells and stimulate cyclic adenosine 
monophosphate (cAMP). This allows calcium to flow into the cell, thereby increasing 
the intracellular calcium concentration, which inhibits ATP-sensitive potassium 
channels. Intracellular calcium enhances the release of preformed insulin granules by 
exocytosis (Holst and Gromada, 2004). 
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1.3.7 Physiological Effects of incretin hormone 
The physiological effects of GLP-1 and GIP can be classified as pancreatic and extra-
pancreatic.  
 
Pancreatic effects  
GLP-1 stimulates glucose-dependent insulin secretion. It may enhance β cell action, 
by inducing the insulin gene and consequently increasing insulin synthesis. 
Additionally, it may inhibit β cell apoptosis (Farilla et al., 2003). Throughout life, β cell 
mass is maintained by equal rates of regenerating new cells and apoptosis. Therefore 
an imbalance of this relationship with increased apoptosis will lead to lower the β cell 
numbers. As such, prospective therapeutic options with incretin therapy aimed at 
reducing β cell apoptosis have been considered.  
GLP-1 inhibits glucagon release from the α cells in a glucose-dependent manner as 
with the β cells (Brubaker, 2010), but it does not affect the counter regulatory effects 
in hypoglycaemia. GIP enhances glucagon secretion (Baggio and Drucker, 2007; Van 
Gaal et al., 2008). 
 
Extra-pancreatic effect 
GLP-1 has a modest effect on inhibiting gastric emptying, which may contribute to the 
suppression of appetite (Brubaker, 2010). The inhibition of gastric emptying was seen 
most clearly during pharmacological elevation of GLP-1 concentration with exenetide 
therapy. Additionally, it inhibits gastrointestinal fat absorption; stimulates the central 
nervous system to mediate insulin release and may potentiate post-meal satiety 
(Baggio and Drucker, 2007). GLP-1 may offer some benefits in the immediate post 
angioplasty state by improving ventricular systolic function, global and regional wall 
motion, respectively (Nikolaidis et al., 2004). GIP inhibits gastric acid secretion (Baggio 
and Drucker, 2007), and also increases fat deposition (Baggio and Drucker, 2007). 
These hormones have been claimed to have an immune-modulatory and neuro-
protective effect. (Ma et al., 2009; Lee et al., 2010). 
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1.3.8 Incretin effect in insulin resistance and type 2 diabetes  
Although the physiological basis for a defect in the incretin effect is elusive, there is 
sufficient evidence to suggest that the incretin effect is impaired in insulin resistant 
state and type 2 diabetes. GLP-1 secretion has been found to be reduced in type 2 
diabetes after a mixed meal (Toft-Nielsen et al., 2001; Vilsboll et al., 2001) and 
attenuated in obese subjects after a carbohydrate meal (Ranganathan and Davidson, 
1996). Additionally, an accelerated deactivation of incretin hormones in type 2 diabetes 
has been reported (Kjems et al., 2003). It was previously thought that the defect in 
incretin system was a feature of pre-diabetic state, rather than a consequence of 
diabetes. However, the demonstration of a normal incretin effect in first degree 
relatives of type 2 diabetes patients, when compared to normal controls, may suggest 
that the defect is a sequel of type 2 diabetes (Nauck et al., 2004).  
DPP-4 inhibitors have been shown to decrease fasting lipolysis (Azuma et al., 2008) 
and postprandial triglyceride (Matikainen et al., 2006), and increase glucose utilization 
(Ahren et al., 2005) in individuals in type 2 diabetes. However, the underlying 
mechanism for those changes have not been defined. 
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1.4 Treatment of type 2 diabetes 
Previous treatment of type 2 diabetes was glucose-centric; and therapeutic 
interventions were mainly focused on reducing fasting blood glucose and HbA1c. This 
was usually achieved with early initiation of insulin therapy at the expense of weight 
gain. Recent insights into the pathophysiology of type 2 diabetes have revealed that 
intra-organ lipid accumulation is central to type 2 diabetes, and that the condition can 
be reversed by decreasing intra-organ lipid accumulation. This heralds a new approach 
to the management of type 2 diabetes and it is relevant to discuss how present 
treatment options influence intra-organ lipid accumulation and overall glycaemic 
control. 
 
 
1.4.1 Lifestyle modification 
Lifestyle modification with weight loss and exercise are fundamental first line 
therapeutic strategies in the management of impaired glucose tolerance and type 2 
diabetes (Knowler et al., 2002). Very often, the clinical relevance of their metabolic 
benefits on glycaemic control is overlooked or unsustainable by patients in clinical 
practice. Weight loss can be efficiently achieved by low calorie diet and exercise plays 
a role in weight maintenance. In some health-motivated subjects, type 2 diabetes can 
be reversed with weight loss and weight gain can be prevented. 
In overweight type 2 diabetes subjects moderate weight loss can improve insulin 
sensitivity and glycaemic control (Bogardus et al., 1985). Weight loss reduces intra-
hepatic lipid content and this is associated with an improvement in hepatic insulin 
sensitivity (Dube et al., 2011; Lim et al., 2011a). In the latter study, a 30% reduction in 
liver triglyceride content within the 7 days was associated with normalization of fasting 
blood glucose; and the reduction in pancreatic fat over 8 weeks was associated with 
normalization of β cell function. Exercise improves peripheral insulin sensitivity but 
does not affect hepatic insulin sensitivity (Dube et al., 2011). It is also known that 
dietary habits are an important risk factor for developing type 2 diabetes (McNaughton 
et al., 2008). Although the most appropriate dietary composition for maintaining normal 
glycaemic control remains unclear, there is growing evidence to suggest that a high 
monounsaturated fatty acid (MUFA) diet may improve insulin sensitivity and β cell 
function (Lopez et al., 2008).
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1.4.2 Biguanide  
Metformin is the only biguanide presently used in clinical practice and it is considered 
as the first drug of choice for the treatment of type 2 diabetes (Inzucchi et al., 2012). 
Although it has been in clinical use for more than five decades, the exact mechanism 
of action of metformin remains elusive, and several mechanisms of action have been 
proposed. It was previously thought that the mechanism of action was mediated 
through activation of adenosine monophosphate-activated kinase (AMPK) (Foretz et 
al., 2010), which phosphorylates the CREB binding protein. Phosphorylated CREB 
binding protein causes the dissociation of the CREB-CBP-TORC2 complex required 
for the gene expression of gluconeogenic enzymes. Recent work suggests that 
metformin inhibits the glucagon signalling pathway in the liver mediated by adenylate 
cyclase; and this results in a reduction in hepatic glucose production (Miller et al., 2013) 
Figure 1.3. 
However, both mechanisms failed to explain a change in hepatic adenine nucleotide 
levels (Hawley et al., 2002). More recent evidence suggests that metformin reduces 
hepatic glucose production by inhibiting mitochondrial glycerophosphate 
dehydrogenase; which regulates both cytosolic and mitochondrial redox states 
(Madiraju et al., 2014). Metformin decreases non-esterified fatty acid (NEFA) and 
cholesterol synthesis via AMPK mediated inhibitory effect on the rate limiting steps of 
the lipid and cholesterol synthetic pathways. Additionally, metformin was found to 
reduce the risk of macrovascular complications in patients with type 2 diabetes 
(UKPDS, 1998).  
In skeletal muscle, metformin increases glucose uptake by 23% during a 
hyperinsulinaemic euglycaemic clamp, via the non-oxidative glucose metabolic 
pathway and GLUT4 translocation (Johnson et al., 1993). An extended release 
formulation limits some of the gastrointestinal side effects commonly seen with the 
standard metformin preparation. Liver triglyceride content does not change with 
metformin therapy (Tiikkainen et al., 2004), and there is no information on the effect 
on pancreas triglyceride content. 
As type 2 diabetes progresses metformin mono-therapy combined with lifestyle 
modification fails to achieve optimal glycaemic control in about 40 - 50% of patients 
after 2 years (Brown et al., 2010). Treatment failure rises to 70% after 3 years (Turner 
et al., 1999; Cook et al., 2007); and 90% after 9 years (Turner et al., 1999). It is often 
16 
 
considered clinically necessary to combine metformin with other oral or injectable anti-
diabetic medications, tailored to the individual need of the patient. 
 
 
 
Figure 1.3 AMPK pathway in hepatocyte (Miller et al., 2013) 
 
 
1.4.3 Sulfonylurea (SU) 
SU is usually added if lifestyle modification and metformin fail to maintain adequate 
glycaemic control. Sulfonylurea promotes insulin secretion by interacting with specific 
sites on the SU receptor on the β cells of the pancreas. This causes the KATP channels 
to close, resulting in the accumulation of intracellular potassium concentration and 
consequently depolarisation of the β cell membrane. Membrane depolarisation causes 
an influx of calcium into the cells, which in turn enhances the exocytosis of insulin from 
the vesicle. There is no evidence to suggest that SU stimulates proinsulin biosynthesis. 
Unlike DPP-4 inhibitors, insulin secretion with SU is not glucose dependent and the 
risk of hypoglycaemia is greater. This is a particular problem if food intake is irregular, 
as may be the case for older people. SU have no effect on intra-organ lipid content. 
Side effects include hypoglycaemia and weight gain. The latter may possibly be as a 
result of the orexogenic effect of high insulin levels; therefore weight typically rises. It 
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has been shown that SU does not lower liver lipid content in type 2 diabetes (Phielix 
et al., 2013). Common side effects associated with SU are hypoglycaemia and weight 
gain. 
SU increases endogenous insulin production irrespective of glucose concentration; as 
such the liver is exposed to high concentration of insulin compared to the peripheral 
metabolic organs. Additionally there is an increase flux of lipids to the liver in type 2 
diabetes. In the presence of hyperinsulinaemia and increase lipid flux, it is likely that 
de novo lipogenesis may increase modestly with SUs. This will happen only as long as 
the β cells are able to produce such elevated levels of insulin. In contrast with 
exogenous therapeutic insulin administration, there is no portal - peripheral gradient of 
insulin concentration and hence this is relatively lower in the hepatic circulation 
compared to that in the periphery. Incretin based therapies decrease lipid flux to the 
liver and reduce hyperinsulinaemia as a result of increased sensitivity to the β cells. 
These fundamental differences in mechanism of action may account for the differences 
in liver triglyceride with SU compared to therapeutic insulin and incretin based 
therapies. 
 
 
1.4.4 Thiazolinedione (TZD) 
TZD is an agonist for the nuclear receptor, peroxisome proliferate activator receptor ƴ 
(PPAR ƴ). Activated PPAR ƴ increases the transcription of specific genes which 
promote insulin sensitivity. PPAR ƴ are expressed abundantly in the adipocytes but 
they are sparsely located in skeletal muscle (Vidal-Puig et al., 1997). Even though the 
distribution of PPAR ƴ receptors has led to some debate about the site of action of 
TZD, there is enough evidence to suggest that in type 2 diabetes the predominant site 
of action is the liver. Ravikumar et al., demonstrated that a 50% reduction in hepatic 
fat with pioglitazone was associated with a 26% suppression of fasting hepatic glucose 
production and a two-fold reduction of postprandial hepatic glucose production 
(Ravikumar et al., 2008). In addition, pioglitazone decreases glucagon and NEFA 
concentration in type 2 diabetes (Ravikumar et al., 2008) (Basu et al., 2008). 
Pioglitazone reduces intramyocellular lipid (IMCL) by 34% in subjects with impaired 
glucose tolerance, associated with a two-fold increase in peripheral insulin sensitivity 
during a glucose tolerance test (Rasouli et al., 2005). In type 2 diabetes, a 55% 
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reduction in IMCL has been reported (Ravikumar et al., 2008). The significant decrease 
in visceral fat to subcutaneous fat ratio, coupled with weight gain, suggests that TZD 
predominantly improves insulin sensitivity by mobilising and redistributing visceral and 
intra-hepatic fat to the subcutaneous tissues. The common side effects of TZD include 
water retention, oedema and weight gain.  
 
 
1.4.5 Sodium glucose co-transporter 2 (SGLT2) inhibitor 
SGLT2 inhibitor is a new class of oral hypoglycaemic agent. The mechanism of action 
is independent of insulin secretion and insulin resistance. SGLT2 inhibitor is a potent 
competitive inhibitors of the SGLT2 receptors located in the proximal tubules of the 
kidney, therefore preventing glucose reabsorption (Han et al., 2008; Grempler et al., 
2012), as such renal glucose excretion is increased and plasma glucose falls. It can 
either be used as mono-therapy or combined with other anti-diabetes medications. 
Combined therapies with SGLT2 inhibitor and metformin have a low risk of 
hypoglycaemia, improve HbA1c by 0.7%, and achieve weight loss of 2.5kg (Haring et 
al., 2014). The weight loss achieved with SGLT2 therapy (Zhang et al., 2010), either 
alone or as part of a combined therapy, may have an indirect effect in reducing hepatic 
steatosis by increasing calorie loss through the kidneys (Tahara et al., 2013). The 
common side effects are urinary tract and genital infections, hypoglycaemia, and 
dehydration. 
 
 
1.4.6 Bariatric surgery 
Bariatric surgery is now recognised as a therapeutic option in obese type 2 diabetes 
to bring about durable weight loss, reduction in intra-organ lipid content and decrease 
in blood glucose concentration for the long term. It is a safe surgical procedure 
performed to reduce the size of the stomach and oral calorie intake with the aim of 
achieving weight loss in obese patients with or without diabetes. Remission of type 2 
diabetes, or a significant improvement in glycaemic control, was observed in a majority 
of obese type 2 diabetes patients after bariatric surgery (Buchwald et al., 2009). 
Marked weight loss after bariatric surgery in obese type 2 diabetes subjects has been 
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found to be associated with resolution of hepatic steatosis in more than 80% of cases; 
and this was associated with an improvement in other metabolic parameters (Clark et 
al., 2005; Furuya et al., 2007). The benefits of bariatric surgery are maintained long 
after surgery as weight gain is inhibited by calorie restriction. Weight loss of about 25% 
of body weight has been found to be associated with significant reduction in 
cardiovascular risks 12 months after surgery (Schauer et al., 2012). Additionally, up to 
42% of patients were free from type 2 diabetes at 1 year (Schauer et al., 2012) and 
38% of patients at 3 years (Schauer et al., 2014). It was previously considered that the 
improvement in metabolic indices observed with bariatric surgery might be mediated 
through the incretin hormones (Laferrere et al., 2007). On the contrary, there is growing 
evidence to suggest that the improvement in glycaemic control post bariatric surgery 
is mediated through a sudden reduction in calorie intake resulting from the procedure 
(Gumbs et al., 2005; Lingvay et al., 2013). Common side effects after bariatric surgery 
are dumping syndrome, hypoglycaemia, and vitamin and mineral deficiencies. 
 
 
1.4.7 GLP-1 agonist 
GLP-1 agonist is a synthetic analogue of the exendin-4 hormone, which is resistant to 
DPP-4 degradation. Exendin-4 hormone was originally isolated from the salivary gland 
of the gila monster, Heloderma suspectum. GLP-1 agonist enhances glucose-
stimulated insulin secretion (Fehse et al., 2005), suppresses glucagon secretion 
(Kolterman et al., 2003), decreases gastric emptying and postprandial hyperglycaemia 
(Zhao et al., 2008) and potentiates weight loss in obese subjects with or without type 
2 diabetes (Brons et al., 2009; Vilsboll et al., 2012). In addition, GLP-1 agonist may 
have some benefits on cardiovascular risk factors.  
GLP-1 agonist has been found to have a clear effect on reducing hepatic lipid content. 
In subjects with type 2 diabetes, 24 weeks of GLP-1 agonist treatment reduced intra 
hepatic lipid content by 42% (Cuthbertson et al., 2012). In a case report, a 66% 
reduction in hepatic lipid content was observed in a poorly controlled type 2 diabetes 
patient after 44 weeks of treatment with GLP-1 agonist (Tushuizen et al., 2006).  
GLP-1 agonist is administered by subcutaneous injection and its low risk of 
hypoglycaemia presents a favourable choice as either monotherapy or in combination 
with either metformin, SU, TZD or with insulin. Exenetide and pioglitazone have been 
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found to have a greater effect in the reduction of hepatic triglyceride content compared 
to pioglitazone only treatment (61% vs. 41%) (Sathyanarayana et al., 2011).  It has 
been suggested that GLP-1 agonist promotes tissue lipolysis and this may possibly 
account for the reduction in liver triglyceride accumulation (Vendrell et al., 2011). The 
most common side effects associated with GLP-1 agonist are nausea and vomiting. 
Commencing GLP-1 agonist at a lower dose reduces the potential risk of side effects. 
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1.4.8 DPP-4 inhibitor 
DPP-4 inhibitor enhances insulin secretion from the β cells only in a glucose-
dependent manner such that they do not enhance insulin secretion when blood 
glucose is low. In addition, it has a modest ability to improve the ability of α cells to 
sense hypoglycaemia and respond appropriately with an increased secretion of 
glucagon (Ahren et al., 2009). These unique characteristics account for the low risk of 
hypoglycaemia, which would otherwise drive defensive eating as a compensatory 
mechanism. This may be the major reason why weight gain is not associated with the 
DPP-4 inhibitors. They can be regarded as weight neutral drugs (Ahren et al., 2010). 
There is sufficient evidence to suggest that maximum clinical benefits are attained 
when a DPP-4 inhibitor is combined with metformin. Weight gain is negligible and 
glycaemic control is comparable to that of other agents (SU, TZD) when used singly or 
in combination with metformin (Ahren et al., 2004; Bosi et al., 2007). The effect of DDP-
4 inhibitor on human liver, muscle and pancreas triglyceride accumulation has not been 
previously studied.  
Vildagliptin is the DPP-4 inhibitor examined in this thesis. It is administered orally and 
was approved for clinical use in 2007 (Nauck et al., 2011). It exerts similar 
pharmacokinetics in normal subjects and in patients with type 2 diabetes (Scheen, 
2010). Vildagliptin is a nitrile-based compound which forms a covalent bond with the 
catalytic site of the DPP-4 enzyme. This process involves two steps: the formation of 
a reversible enzyme-inhibitor complex followed by slow dissociation of the covalent 
bond (Nauck et al., 2011). The slow dissociation of the vildagliptin-DPP-4 bond 
explains the increased potential of this drug to augment the amounts of intact 
endogenous GLP-1 and GIP concentration (Ahren et al., 2011). GLP-1 and GIP 
increase the sensitivity of the α- and β-cells to glucose and this is accepted as its major 
mechanism of action (Ahren et al., 2011; JE, 2014). Vildagliptin is known to reduce or 
delay postprandial lipid absorption (Matikainen et al., 2006) as well as reduce 
postprandial triglyceride concentration and lipolysis (Matikainen et al., 2006; Derosa et 
al., 2014). 
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1.5 Magnetic Resonance Imaging 
Nuclear magnetic resonance (NMR) is a physical phenomenon that arises from the 
interactions between an atom’s nucleus and a magnetic field. This phenomenon is the 
fundamental principle of magnetic resonance imaging (MRI) and magnetic resonance 
spectroscopy (MRS), which allows the detection and identification of some 
nuclei/metabolites. As tissues differ in composition and physical properties, NMR can 
be used to differentiate them and also provide a non-invasive, non-ionising method of 
obtaining images and making in vivo measurements of metabolites in humans. These 
unique properties make it well suited to the present purpose of performing repeated 
measurements of liver and pancreas fat content, liver and skeletal muscle glycogen 
concentration, and pancreas volume. 
 
 
1.5.1 BASIC PRINCIPLE OF NMR 
An atom consists of negatively charged electrons revolving around a nucleus that is 
made up of neutrons (neutrally charged) and protons (positively charged). Some nuclei 
possess a magnetic property called ‘spin’, which results in an interaction between the 
nucleus and a scanner’s magnetic field. Nuclei with spin will resonate (absorb) energy, 
allowing detection by the scanner at a frequency determined by the strength of the 
scanner’s magnetic field, the type of nucleus and the chemical identity of the molecule 
containing the nucleus. NMR allows us to identify and quantify metabolites in a tissue 
from their different resonant frequencies. 
When a patient is positioned in a scanner, the nuclei of metabolites interact with the 
scanner’s magnetic field by aligning its field to that of the scanner. Applying a radio-
frequency (RF) pulse specific for a particular nucleus through a transmitter coil excites 
the nucleus. This will consequently produce a signal, which can be detected by the 
receiver coil. The NMR signal detected by the scanner is called Free Induction Decay 
(FID); it represents the oscillating signals from the nuclei in the sample. Fourier 
transformation of the FID produces a spectrum, which is a plot of signal intensity 
against frequency. The spectrum shows signals from the nuclei with different resonant 
frequencies as individual peaks, thus separating signals from different molecules in a 
tissue Figure 1.4 (Butler, 2002). 
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Figure 1.4 Signal emitted by an excited nucleus  displayed in free induction decay (FID) 
format and transformed to intensity-frequency domain by Fourier transformation 
(Butler, 2002) 
 
The area under the peak can be used to calculate the concentrations of the metabolite 
of interest. The concentration of the metabolite can be determined by either comparing 
it with that from a standard solution (phantom), with known concentration of the 
metabolite of interest, or an intrinsic compound, with known concentration, e.g. water 
peak of skeletal muscle. 
 
 
1.5.2 FUNDAMENTAL PROPERTIES OF NMR SIGNAL 
Chemical shift, spin-spin coupling and relaxation are NMR properties determined by 
the nuclei, metabolite and tissue that influence the detected NMR signal. 
 
 
 Chemical shift 
Chemical shift is a characteristic that allows us to distinguish between different 
molecules / chemicals that contain the same nuclei. The resonant frequency of a 
nucleus is determined by the chemical composition of its molecules as well as the 
magnetic field of the scanner, as the molecule alters the magnetic field at the nucleus. 
To illustrate this concept, 1H NMR spectrum of acetic acid (CH3COOH) can be 
considered. The protons from the methyl (-CH3) moiety resonate at a higher frequency 
than the proton of the carboxyl (-COOH) moiety, because the moieties experience a 
different chemical environment Figure 1.5. The signal intensity is also dependent on 
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the number of nuclei contributing to that signal (three protons from the -CH3 moiety 
and one from the -COOH moiety). Therefore, the intensity from the -CH3 moiety is three 
times greater than that from the -COOH moiety. Additionally, the electrons 
continuously revolving around the nucleus provide a shielding effect to the nuclei. The 
shielding effect can be described as the magnetic field effect of the electrons 
surrounding the carbon nucleus, hence, the magnetic effect of the carboxyl group on 
its carbon nucleus will exert a greater shielding effect, contributing to the higher 
resonance frequency of the -COOH moiety when compared with the signal frequency 
of the -CH3 moiety, which has less shielding effect. The relative displacement of the 
spectral peaks is measured in parts per million (ppm). 
 
 
 
Figure 1.5 1H NMR spectrum of acetic acid (CH3COOH) showing relative areas of the 
signal with a ratio of 3:1 (Gadian, 1985) 
 
 
1.5.3 Chemical shift 
Chemical shift can be used to differentiate between triglyceride within the myocytes 
i.e. intramyocellular lipids (IMCL) and that out of the myocytes i.e. extramyocelluar 
lipids (EMCL). The alignment of muscle fibres will influence the magnetic field around 
the IMCL and consequently produce a different lipid proton resonant frequency from 
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that of EMCL. This has enabled investigation of the effect of IMCL on insulin sensitivity 
in skeletal muscle. 
 
 
 Spin decoupling 
When a RF pulse excites 13C nuclei in carbon compounds, the signal produced 
contains multiple peaks for a carbon nucleus that is covalently bonded to one or more 
hydrogens. This phenomenon, referred to as spin-spin coupling, results from the 
interaction between the magnetic fields of each proton, their neighbouring 13C atoms 
and the scanner. The complex multi-peak spectrum can be simplified by applying a 1H 
RF pulse during 13C signal acquisition. This process is referred to as spin decoupling. 
Spin decoupling is used in 13C spectroscopy to simplify the spectra and aid 
identification and quantification of carbon-based metabolites such as glycogen.   
 
 
 Relaxation 
When protons are excited by a radio-frequency pulse (RF), they absorb energy and 
resonate, generating the NMR signal. The protons relax back to equilibrium by two 
processes: T1 and T2 relaxation. T2 relaxation represents the de-phasing of spins after 
their phase coherence; and T1 represents the return of the nuclei to their original 
realignment / energy levels after excitation by the RF pulse. 
 
 
1.5.4 The effect of noise on signals 
During acquisition of NMR images, the receiver coil detects signal from the sample and 
radiofrequency noise. In humans, normal physiological activities of charged ions such 
as nerve conduction or cell function creates a current. The current generates an 
alternating magnetic field which produces a noise signal that can also be detected by 
the receiver coil. Noise produced by these electrical activities described is displayed 
together with the signal from the nuclei of the desired molecule, hence the images and 
measurements of the metabolites of clinical interest are obscured. Increasing the 
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magnetic field strength can increase the magnitude of the metabolite signal relative to 
the noise, and scan protocols used for the study are optimised to ensure sufficient data 
quality can be obtained. 
 
 
1.5.5 Surface coils  
Surface coils are sensors used to detect signals from nuclei in a defined volume of 
tissue such as the liver, pancreas and skeletal muscle. They are held in place directly 
over the anatomical area and are required to be perpendicular to the scanner’s 
magnetic field for signals to be detected. Surface coils are used to study organs close 
to the skin because the intensity of received MR signals decreases as the distance 
from the coil increases. In the studies required in this thesis, surface coils were used 
to measure liver and skeletal muscle glycogen concentration. 
 
 
1.5.6 Magnetic Resonance Spectroscopy 
In metabolic studies, MRS is a safe, non-invasive alternative to organ biopsy to 
measure glycogen and lipid concentration in the liver and skeletal muscle. This 
property enables the assessment of the effect of a new DPP-4 inhibitor on dynamic 
glycogen storage in skeletal muscle and liver, and measure any change in lipid 
concentration in skeletal muscle.  
 
 
 1H nucleus and MRS 
1H spectroscopy can be used to identify and measure the concentration of lipid in the 
different cellular components (intramyocellular and extramyocellular) of skeletal 
muscle (Schick et al., 1993). 1H has a natural abundance of 99.98% and is the most 
sensitive nucleus for MRI compared with that of 13C and 31P. 1H signal from fat and 
water can be adequately obtained and quantified in man, given that the human body 
contains fat and water, both of which are proton rich. 1H spectroscopy is well suited to 
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measure and quantify the fat content of muscle in type 2 diabetes and also to evaluate 
the effect newer therapies such as DPP4-inhibitors may have on these fat stores. 
The coefficient of variation for measuring IMCL with 1H spectroscopy in obese and 
non-obese subjects is 7.9% and 11.8%, respectively (Schick et al., 1993). 1H 
spectroscopy provides a feasible and accurate methodology for quantifying IMCL when 
compared to other conventional methods such as electron microscopic morphometry 
and biochemical analysis from muscle biopsy (Schick et al., 1993).  
 
 
 13C MR spectroscopy 
13C spectroscopy can be used to measure glycogen concentration in liver and skeletal 
muscle. 13C has a natural abundance of 1.1% and is less sensitive than 1H nucleus in 
MRS. As the MR signal from glycogen is small, the measurement of liver glycogen is 
extremely difficult in obese subjects with significant subcutaneous fat, as this increases 
the separation between RF coil and the liver. Measuring glycogen concentration with 
13C MR spectroscopy methodology has been validated against direct biochemical 
assay of muscle biopsy, and a very strong correlation between the two methodologies 
has been demonstrated (r = 0.95; p< 0.0001) (Taylor et al., 1992). Additionally, 13C MR 
spectroscopy was shown to be more precise than biochemical assays of needle biopsy 
with a coefficient of variation of 4.3 ± 2.1% compared with 9.3 ± 5.9% with the biopsy 
(Taylor et al., 1992).  
 
 
1.5.7 Image-based measurements of tissue fat content:  Three-point Dixon MRI 
Based on the chemical shift differences between fat and water protons, MRI can be 
used to quantify intra-organ fat content. The Dixon method exploited these concepts 
and employed a two-echo approach (in-phase and out-of phase) known as two-point 
Dixon technique to acquire separate fat and water images (Dixon, 1984). Over the 
years, this method has been extended to a three-echo approach to acquire fat and 
water images corrected for homogeneity of the magnetic field, B0 and poor shimming 
(Glover and Schneider, 1991). Dixon MRI of the liver requires a breath hold during 
acquisition of images, thus preventing contamination of the liver and pancreas MR 
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signal by a signal from surrounding structures. The Dixon method allows separation of 
fat and water signals to accurately quantify the fat portion in organs. It provides 
sufficient spatial resolution and anatomical detail from which the volume of organs or 
intra-organ fat can be estimated. Figure 1.6 shows images obtained by the three-point 
Dixon method with water percentage and fat percentage images of both the liver and 
pancreas, respectively. It has been demonstrated that there is a strong correlation and 
agreement between the Dixon method and MRS methodology in quantifying liver fat (r 
= 0.95; p <0.0001) and pancreas fat (r = 0.51; p < 0.02) (Hu et al., 2010). It was 
suggested that the lower correlation co-efficient observed with pancreas fat 
measurement was due to technical difficulty and poor operator expertise in identifying 
the region of interest in the pancreas with the Dixon method while movements with 
respiration contributed modestly (Hu et al., 2010). To circumvent this problem, 
operators require to be fully trained in drawing regions of interest (ROIs) in the Dixon 
images and need to have background knowledge in human anatomy. Also, the MRS 
methodology does not offer the luxury of identifying the structure from which the 
spectra was obtained, making it impossible to identify any contamination from 
neighbouring structures. Respiratory movements are very likely to allow visceral fat to 
enter the ROI identified for signal collection from the pancreas. There was no 
statistically significant bias between the two methods in measuring liver fat. The bias 
between Dixon and MRS methodology in measuring liver fat calculated with a Bland-
Altman plot, was reported as 0.38% (95% confidence interval (-3.5% to 4.3%, p = 0.4) 
(Hu et al., 2010).  The reproducibility of liver and pancreas fat measurement with the 
Dixon technique is higher than that with the MRS methodology, thus making it suitable 
for our study requiring repeated measurements. Tushuizen et al., reported a Bland-
Altman repeatability coefficient of variation for liver and pancreas fat analysis with MRS 
as 4.7% and 15.2%, respectively (Tushuizen et al., 2007). Additionally, in another 
study, Lim et al., also reported that the repeatability coefficient of variation for liver and 
pancreas fat measurements with the Dixon technique was 0.5% and 0.9%, respectively 
(Lim et al., 2011).  
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Figure 1.6 Demonstrates three point Dixon images of the liver and pancreas with fat 
(top), water (middle) and percentage of fat in MR signal (bottom) of the liver and 
pancreas
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1.5.9 Balanced Steady State Free Precession (BTFE) Images  
As the measurement of pancreas volume with NMR has not been previously 
documented, new techniques for measuring pancreas volume with Balanced Steady 
State Free Precession (BTFE) structural MRI scans were devised. Application of 
magnetic resonance technology to the pancreas is in its infancy. However, it holds 
great promise as a tool to investigate both changes in pancreas volume in response to 
therapy and long term changes during the natural history of type 2 diabetes.   
Although type 2 diabetes does not develop without dysfunction of β cells, the pancreas 
is the least studied organ in this condition.  
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1.6 Aim of the study 
The aim of this work is to elucidate the overall physiological effects of the DPP-4 
inhibitor, vildagliptin in view of suggested effects on insulin sensitivity and lipid 
metabolism.  
Specifically, effects upon insulin sensitivity of the liver and skeletal muscle were to be 
evaluated using the euglycaemic hyperinsulinaemic clamp and isotopically labelled 
glucose infusion. Both oxidation and non-oxidative metabolism must be examined to 
allow understanding of the mechanism of action, as any change in insulin sensitivity of 
a tissue may be caused by change in intracellular fatty acid availability. The triglyceride 
content of liver and skeletal muscle was to be examined using magnetic resonance 
methodology. 
The question of whether DPP-4 inhibition could affect progression of the disease 
towards the need for insulin therapy has been raised. The possible effect of DPP-4 
inhibition on pancreas fat content was to be defined. To achieve this aim, a group of 
44 patients with type 2 diabetes was studied over a 6-month period. Successful 
recruitment and retention of volunteers was central to the success of the whole project. 
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CHAPTER 2 METHODS 
2.1 Research subjects 
2.1.1 Subject recruitment 
A double blinded, controlled, randomised trial was designed in order to evaluate 
possible additional mechanism of a DPP-4 inhibitor (vildagliptin). As vildagliptin takes 
about 3 - 4 months to exert maximum clinical benefits, the type 2 diabetes subjects 
were studied for 6 months to ensure that assessments were made after optimal 
benefits of vildagliptin were achieved Figure 2.1.  A control group of glucose tolerant 
subjects was also studied on one occasion to define the extent of change toward 
normal observed during vildagliptin therapy in the type 2 diabetes group. Normal 
glucose tolerance was demonstrated in all control subjects by normal response to 75g 
oral glucose tolerance test (mean fasting plasma glucose 5.3±0.1mmol/l; 2h 
5.5±0.4mmol/l). 
Inclusion criteria for the type 2 diabetes group were: HbA1c ≤ 7.6% (60mmol/mol), a 
BMI of 22 - 38kg/m2, age 18 - 70 years and at least a 6 month history of type 2 diabetes. 
Eligible subjects must have been on a stable metformin dose of at least 1000mg 4 
weeks prior to the screening visit and have been taking metformin for at least 3 months. 
Exclusion criteria were: previous insulin therapy and chronic oral or parenteral steroid 
therapy; significant ischaemic heart disease in the previous 6 months; kidney 
dysfunction indicated by creatinine levels ≥132µmol/l for males and ≥123µmol/l for 
females; liver impairment indicated by alanine aminotransferase (ALT) >90U/L and or 
aspartate aminotransferase (AST) >82U/L, total bilirubin >42µmol/l and or conjugated 
bilirubin >7µmol/l; fasting triglyceride >5.62mmol/l; ventricular arrhythmias; second and 
third degree AV block or prolonged QTc. It is worth noting that a cut off HbA1c >7.6% 
(60mmol/mol) was chosen to avoid any big change in plasma glucose concentration. 
Subjects were recruited by newspaper adverts in Tyne and Wear and Durham. In 
addition, searches from General Practice (GP) and primary care research network 
databases in the same regions were carried out to identify potential volunteers.  
For the normal control group, glucose tolerant subjects were recruited to match the 
weight, BMI sex and age of subjects in the diabetic group. These volunteers were 
similarly recruited by newspaper adverts and only had baseline MR studies.
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Figure 2.1 General overview of the study design for type 2 diabetes subjects 
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2.1.2 Informed consent procedures 
Subjects wishing to participate in the study expressed their interest via telephone or by 
returning reply slips. Patient information sheets containing full description of the study 
were mailed out. They were then offered an informal visit to the Newcastle Magnetic 
Resonance Centre (NMRC) to discuss the study and matters arising from the 
information sheet. If they agreed to participate, subjects were invited for a screening 
visit, during which further explanation was given. Informed, written, witnessed consent 
was obtained. Prior to obtaining informed consent, it was explained that withdrawal 
from the study at any time was permitted and signing of the consent form did not oblige 
binding them to participate. Out of 65 volunteers screened, 44 met the inclusion criteria 
and were enrolled in the study. The most common reason for exclusion was HbA1c ≤ 
7.6% (60mmol/mol). The study protocol was reviewed and approved by the Newcastle 
and North Tyneside 2 Research Ethics Committee. 
 
 
2.2  Statistical methods 
Statistical analysis was performed with Graphpad Prism 6.0d software. Data are 
expressed as mean±SEM. Students two-tailed paired t-test or the Mann-Whitney test, 
and one-way ANOVA were used to compare groups as appropriate. Pearson 
correlation was used to assess relationship between variables. Statistical significance 
was defined as p<0.05.  
Sample size calculation was based on detecting a difference in the mean change from 
baseline to 6 months in whole body insulin sensitivity (Rd) during the hyperinsulinaemic 
euglycaemic clamp between the metformin/vildagliptin treated and metformin/placebo 
treated group. 30% (1.65mg/kg/min) increase in Rd in the metformin/vildagliptin treated 
was considered clinically significant. Standard deviation was assumed as 
1.55kg/mg/min (Bogardus et al., 1984), 2 sided significant level of 5% and a desired 
power of 90% was considered appropriate. A sample size of 40 patients was allocated 
to either metformin/vildagliptin treated and metformin/placebo treated group in a 1:1 
ratio. Additionally 4 patients were recruited to allow for a 10% drop out rate without any 
significant effect on the power of the study. Power calculation were performed using 
the nQuery Advisor® version 6.01 software. Based from observation from a previous 
study (Azuma et al., 2008), it was felt that 6 months of treatment was appropriate to 
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examine the effect of vildagliptin on whole body insulin sensitivity and also investigate 
chronic changes in triglyceride and glycogen storage in the liver and muscle.
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2.3 Anthropometric measurements and body composition 
2.3.1 Body Mass Index 
Subjects were weighed using an accurate weighing scale (SECA SCALES, Germany) 
wearing indoor clothing only. Prior to weighing, it was ensured that the scale was 
horizontal by the use of an integral spirit level and was not disrupted during 
measurements. Height was measured with a stadiometer (SECA SCALES, Germany) 
and BMI was calculated as weight (kg) divided by the square of height (m2). 
 
 
2.3.2 Waist-hip ratio  
All measurements were made with a non-distensible tape measure, with subjects in a 
relaxed standing position. The waist was assumed to be the mid-point between the 
lower edge of the ribcage superiorly and the anterior superior iliac spine inferiorly. Hip 
measurements were taken at the level of the greater trochanter. The waist and hip 
measurements were expressed as a ratio. 
 
 
2.3.3 Bio-electrical impedance 
Bioelectrical impedance was used to determine percentage body fat with a Bodystat 
1500 machine. This required input of the height, weight and activity level of the 
volunteer. This technique depends on measuring the resistance to a very small current 
applied through the electrodes. The resistance of the tissues is proportional to the 
water content as the electrical current is conducted through the electrolyte solution. 
Fat does not contribute to this, therefore the impedance of water and fat is 
differentiated and can be measured. The repeatability of the Bodystat 1500 machine 
was assessed for a single volunteer on 10 different occasions. The intra-subject 
coefficient of variation (CV) was calculated by dividing the standard deviation of these 
results by the mean, then multiplying by 100 to express as a percentage. The CV was 
found to be 6.0%. 
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2.4 Metabolic studies 
2.4.1 Cannulation and blood sampling 
An 18 gauge cannula was inserted into a vein in the subject’s hand or wrist, and flushed 
with 5mls of 0.9% normal saline to maintain patency of the cannula. This hand was 
placed in an in-house built hand-warming device, heated to 55°C to achieve 
arterialisation of venous blood. Discarding the initial 2mls of blood withdrawn and using 
a new syringe to obtain blood samples, the dilution of samples with saline flushes was 
avoided. The samples were centrifuged and separated; plasma was stored 
immediately at -40°C at the NMRC and later transferred to the Diabetes Research 
Laboratory in ice for assaying of plasma insulin, glucagon, NEFA, triglyceride, atom 
per cent excess (APE) of 6' 6' - dideuterated glucose. A second 18 gauge cannula was 
inserted in a large ante-cubital vein in the contra-lateral arm to administer infusions (6' 
6' - dideuterated glucose, insulin and 10% Dextrose as appropriate). Care was taken 
to minimise any discomfort to the subject during cannulation. 
 
 
2.4.2 Combined metabolic investigations 
Subjects were advised to abstain from vigorous exercise and smoking for 3 days prior 
to metabolic test days. On a metabolic test day combined assessments for hepatic 
glucose production (HGP), glucose and lipid oxidation were made at specific time 
points. Hepatic insulin sensitivity and whole-body insulin sensitivity (Rd) were 
calculated from measuring plasma tracer concentration and glucose infusion rate, 
respectively, as described Figure 2.2. A bolus of 10% 6' 6' - dideuterated glucose was 
given as the priming dose at time -180 minutes. The 2% 6' 6' - dideuterated glucose 
infusion was commenced immediately and continued to the end of the insulin infusion 
period (time 180 minutes). During the last 30 minutes of both the basal and insulin 
infusion period, it was assumed that a steady-state milieu is achieved, thereby allowing 
assessments to be made. Samples for basal HGP, plasma glucose, insulin and 
glucagon analysis were obtained over the last 30 minutes of the basal period (from -
30 minutes to 0 minutes) and the insulin infusion period (time 150 minutes to 180 
minutes). Similarly, indirect calorimetry for measuring glucose and lipid oxidation was 
done during the last 20 minutes of the basal period (from time -20 minutes to 0 minute) 
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and insulin infusion period (from time 160 minutes to 180 minutes). Insulin infusion was 
commenced at time 0 minute and continued for 180 minutes. 
Hepatic insulin sensitivity was calculated as the difference between HGP measured 
during the basal and insulin infusion periods, expressed as a percentage. The glucose 
infusion rates recorded during the last 30 minutes of the insulin infusion period was 
used to calculate Rd.  
 
 
 
Figure 2.2 Metabolic test day demonstrating the time points for measuring HGP (basal 
and clamp), glucose oxidation and peripheral insulin sensitivity (Rd)
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2.5 Hepatic glucose production 
2.5.1 Clinical procedure 
The quantification of hepatic glucose production in the basal and hyperinsulinaemic 
periods serves as a useful marker for assessing hepatic insulin sensitivity. The 
preferred method of assessing hepatic glucose production with tracers is now 
established. 6' 6' - dideuterated glucose was infused from 2.5 hours before samples 
were taken for analysis in the basal state, thus allowing proper equilibrium with the 
subject’s plasma.  During steady-state conditions the rates of glucose utilization and 
production are equal and consequently plasma glucose concentration remains stable. 
Endogenous glucose concentration was calculated by subtracting the calculated 
exogenous component and 6' 6' - dideuterated glucose concentration from the 
measured total glucose concentration.  During the hyperinsulinaemic phase 6' 6' - 
dideuterated glucose was infused as in the basal state. In the clamp phase unlabelled 
glucose is added to the plasma pool by variable 10% Dextrose infusion (known) and 
by HGP (unknown), hence HGP can be calculated. 
Under sterile conditions, 6' 6' - dideuterated glucose was made up to 10% strength 
solution. In order to achieve early steady-state isotope enrichment in plasma, a priming 
dose of 10% strength 6' 6' - dideuterated glucose adjusted for fasting blood glucose 
was given to the subjects at the start of the basal period (Hother-Nielsen and Beck-
Nielsen, 1990; Ravikumar et al., 2008). The priming dose was calculated as fasting 
plasma glucose multiplied by 0.6. The rest of the 10% strength 6' 6' - dideuterated 
glucose solution was made up to 2% strength. After infusing the bolus, 2% strength 6' 
6' - dideuterated glucose was infused at 0.04mg/kg/min until the end of the insulin 
clamp period to achieve equilibrium of plasma atom per cent excess (APE) of 6' 6' - 
dideuterated glucose. A 1ml sample of the 2% strength 6' 6' - dideuterated glucose 
labelled ‘NINF’ was taken for analysis for tracer enrichment (enrichmentinf). The 10% 
glucose used to maintain euglycaemia during the clamp was enriched with 2% 6' 6' - 
dideuterated glucose to prevent loss of plasma atom per cent excess (APE) of 6' 6' - 
dideuterated glucose. A 1ml of 10% glucose enriched with 2% 6' 6' - dideuterated 
glucose labelled ‘GINF’ was taken for analysis.
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2.5.2 Gas chromatography mass spectrometry analysis 
Frozen plasma samples for 6' 6' - dideuterated glucose were allowed to thaw for 30 
minutes and then vortex mixed to ensure homogeneity of the sample. 200µl of 
acetonitrile:ethanol (2:1) was added to 30µl of thawed plasma sample. This solution 
was vortex mixed again, then spun in a micro-centrifuge at 13000rpm for 5 minutes at 
room temperature, to facilitate complete precipitation of plasma proteins and 
separation of the supernatant. 200µl of supernatant was pipetted into a 5ml glass vial, 
which was then transferred into a thermoblock sited in a fume hood. The thermoblock 
was set at 90ºC and gentle steam of dry air was made to pass through the thermoblock 
from the top of the 5ml glass tube for 45 minutes to ensure complete dryness of the 
5ml glass vial. The 5ml glass vial was then removed from the thermoblock, but held in 
the fume hood. 60µl of 99.8% anhydrous Pyridine (SIGMA, St Louis USA) and 20µl 
98% anhydrous Acetic Anlydride (SIGMA, St Louis USA) was added to the 5ml glass 
vial in succession. The 5ml glass vial was capped tightly, agitated and transferred to 
an incubator set at 90ºC to dry for 30 minutes until a pale yellow hue in the vial was 
noted. The 5ml glass vial was re-transferred to the fume hood, de-capped and put in 
the thermoblock to dry for 5 minutes. The 5ml glass vial was removed from the fume 
hood and allowed to cool at room temperature for 5 minutes. 75µl of Acetoniitrile 
(SIGMA, ST Louis USA) was added to the 5ml glass vial and gently agitated. 20µl of 
solution was transferred from the 5ml glass vial to a mass spectroscopy vial 
(CHROMACOL 03-FIV, UK) containing 80µl of Acetonitrile (SIGMA, ST Louis USA) to 
allow 1:5 dilution. The 1:5 dilution was essential to prevent overloading of the column 
in the mass spectrometer. 
 A Thermo ‘Voyager’ single quadruple mass spectrometer, attached to a Thermo 
‘Trace’ gas chromatography with automated injection Thermo ‘AS2000’ auto sampler 
(Thermo Scientific – Waltham MA, USA) was used for gas chromatography mass 
spectrometry analysis. The Xcaliber version 1.3 (Thermo Finnigan 1998-2001) 
software was used to make automated settings.  
The auto sampler was set as follows: volume of sample injected 3µl, injection delay 
0.2 seconds, injection speed 50µl/sec. The auto sampler was set to complete a series 
of 2 pre-injection and 5 post injection washes with 5µl of Ethyl Acetone (BDH 
Chemicals Ltd, Poole UK) each time. The split mode was set at 30:1 and the injection 
port was maintained at 220ºC.  
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The gas chromatography was set as follows: gradient length 12.5 minutes, preparation 
run time 10 minutes; equilibration time 30 seconds; temperature range of 200ºC - 
350ºC. Two ramps were set to run at 5ºC/min and 30ºC/min, respectively. Helium was 
used as a carrier gas and the flow rate was set at 1ml/min.  
The mass spectrometer was set in electron ionisation mode with the following settings: 
source temperature 200ºC, interface temperature 250ºC, multiplier voltage 450 volts, 
scan time 0.05 seconds, peak format centroid. The full scan method was used to detect 
all ions. The Qual Browser software was used to filter, identify and record ion mass at 
200 (normal glucose) and 202 (6' 6' - dideuterated glucose) APE values, respectively. 
 
 
2.5.3 Calculation of hepatic glucose production (HGP) 
HGP was calculated by using the model described by Steele et al (Steele et al., 1965). 
The only tissues capable of de-phosphorylating glucose-6-phosphate and releasing 
glucose are the liver and the kidney. The kidney contributes very little to 
gluconeogenesis; and in practice, the liver accounts for about all endogenous glucose 
production (Ekberg et al., 1999). Basal HGP or glucose appearance (Ra) was 
assessed during the last 30 minutes of the 180 minutes basal period and calculated as 
follows (Inzucchi et al., 1998). 
Basal HPG = {[TIR × enrichmenttracer (NINF)] ÷ tracer enrichment in plasma} – TIR 
Where TIR is the tracer infusion rate, enrichmenttracer (NINF) is the APE of 2% strength 
6' 6' - dideuterated glucose infusion. Clamp HGP was assessed during the last 30 
minutes of the 180 minutes hyperinsulinaemic euglycaemic clamp and calculated as 
follows (Inzucchi et al., 1998). 
Clamp HGP = GIFmean × [(enrichmentinf ÷ enrichmentplasma)] – 1 
 
Where GIFmean is the mean glucose infusion rate during the last 30 minutes of the 
hyperinsulinaemic euglycaemic clamp, enrichmentinf is the APE of 2% strength 6' 6' - 
dideuterated glucose in the 10% Dextrose, and enrichmentplasma is the APE of plasma 
6' 6' - dideuterated glucose in the last 30 minutes of the clamp when steady state 
conditions are achieved. 
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2.6 Measurement of whole-body insulin sensitivity  
2.6.1 Euglycaemic hyperinsulinaemic clamp 
The euglycaemic hyperinsulinaemic clamp was employed to measure overall insulin 
sensitivity (Rd). After an overnight fast, the subjects were transported to the NMRC by 
taxi. Cannulation was normally completed by 0845h. Insulin (Actrapid: Novo Nordisk, 
Bagsvaerd, Denmark) dose was calculated according to body surface area (BSA) and 
infused at 40mU/m2/min.  
BSA was calculated with the Du Bois formula (Dubois and Dubois, 1989) as: 
BSA (m2) = 0.20247 × Height 0.725 (m) × Weight 0.425 (kg) 
Then, the insulin dose (ID) calculated as: 
 
ID =  
BSA (m2) × 0.04 (U) × 60 (min) × 50ml (syringe volume)
15 ml/h(constant infusion rate)
 
 
The measured dose of insulin was transferred to a labelled syringe containing 50ml of 
0.9% normal saline. Insulin was infused in two stages: priming and continuous infusion. 
The priming stage was further divided into two phases, A and B. In the priming part ‘A’ 
phase, the calculated insulin dose rate was multiplied by 4 to determine the priming 
dose ‘A’. Insulin was infused at this rate for the first 4 minutes. In the priming part ‘B’ 
phase the calculated insulin dose rate was multiplied by 2, to determine the priming 
dose ‘B’. Insulin was infused at this rate from 4 to 7 minutes. In the continuous stage 
from 7 to 180 minutes, insulin was infused at the calculated dose. 
Plasma glucose concentration was allowed to reach euglycaemia defined as 5.5mM 
by 150 minutes and maintained at this level until completion of the clamp at 180 
minutes (DeFronzo et al., 1979). Euglycaemia was maintained by varying the rate of 
infusion of 10% Dextrose enriched with 2% 6' 6' - dideuterated glucose. To achieve 
this, blood samples were taken at 5 minute intervals and glucose concentration was 
measured with Yellow Springs glucose analyser (YSI, Ohio, USA). The mean 
coefficient of variation of plasma glucose concentration and glucose infusion in the last 
30 minutes of the clamp were 3.3% and 10.0%, respectively.
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2.6.2 Calculation of whole body insulin sensitivity (Rd) 
Whole body insulin sensitivity (Rd) was determined during the last 30 minutes of the 
euglycaemic hyperinsulinaemic clamp (DeFronzo et al., 1979). During the insulin 
infusion period, the rate of infusion of 10% Dextrose enriched with 2% 6' 6' - 
dideuterated glucose was adjusted as required to maintain euglycaemia of 5.5mmol/. 
Rd was calculated from the mean of glucose infusion rate during this period and 
expressed in (mg/kg/min) (Rizza et al., 1981).  
 
 
2.6.3 Rd/Insulin 
During a hyperinsulinaemic euglycaemic clamp, insulin primarily drives glucose 
disposal to muscle. Therefore the rate of insulin clearance will influence the rate of 
glucose disposal to muscle. The Rd/Insulin eliminates the inter-personal variation of 
insulin clearance in a subject. Rd/insulin (ml/kg/min/pM) was calculated as Rd divided 
by steady state plasma insulin concentration. Steady state plasma insulin was 
calculated as the mean plasma insulin concentration obtained at 150, 165 and 180 
minutes. In practical terms it should be considered that the relationship between Rd 
and steady state plasma insulin concentration is not linear, but sigmoidal. 
 
 
2.6.4 Homeostatic model assessment (HOMA) 
The homeostatic model assessment of insulin resistance (HOMA-IR) and β cell 
function (HOMA-β) are simple tools used to quantify insulin resistance and β cell 
function in the basal fasting state. It has been demonstrated that insulin resistance 
quantified by (HOMA-IR) in type 2 diabetes and normal glucose tolerant subjects 
correlated with that estimated by hyperinsulinaemic euglycaemic clamp (r=0.88; 
p=0.0001); likewise β cell function (HOMA-β) correlated with hyperinsulinaemic 
hyperglycaemic clamp (r=0.61; p<0.01) (Matthews et al., 1985). HOMA-IR and HOMA- 
β are calculated as follows:
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HOMA-IR (µU/mol/L3) =   
Fasting plasma insulin x Fasting plasma glucose
22.5
 
 
 
HOMA-β (%) = 
Fasting plasma insulin × 20
Fasting plasma glucose -3.5
 
 
 
It would have been impractical to perform monthly hyperinsulinaemic euglycaemic 
clamps. Consequently, these parameters were used to describe month by month 
change, thereby allowing comparison of any rate of change of insulin resistance and 
sensitivity between groups. 
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2.7 Substrate metabolism with indirect calorimetry 
Indirect calorimetry allows measurement of glucose and lipid oxidation by quantitation 
of O2 uptake and CO2 production. Subjects were made comfortable in the supine 
position. A clear Perspex canopy hood was placed over the head of the subjects. They 
were asked to breathe normally and to avoid talking and sleeping. A pump extracted 
expired air and VO2 and VCO2 were analysed by metabolic cart sensors at 5 second 
intervals. VCO2 is measured by an infrared digital sensor, with a measuring range of 0 
- 10% and an accuracy of 0.02% (Blond et al., 2011). Oxygen was measured with a 
paramagnetic sensor with a measuring range of 0 - 30% and with similar accuracy to 
CO2 (Blond et al., 2011). The flow rate was adjusted to maintain the Fractional inspired 
carbon dioxide (FiCO2) of 0.8% - 1.0%, when measurements of VO2 and VCO2 are 
optimal. Measurements were made over 20 minutes during the last 30 minutes of both 
the basal period (-30 to 0 minute) and the insulin infusion period (150 to 180 minutes). 
Prior to commencing the measurements of glucose and lipid oxidation, the metabolic 
monitor was calibrated using a standard gas to ensure consistency of the flow meter 
and gas analysers. 
 
 
2.7.1 Measuring substrate metabolism with the Quark RMR 
The Deltratac ‖TM metabolic monitor which had previously been regarded as the gold 
standard for indirect calorimetry, was no longer serviced by the manufacturers. 
Malfunction of the Deltratac ‖TM metabolic monitor after the first 6 months of metabolic 
studies caused replacement by the Quark RMR (COSMED, Italy). Prior studies by 
Blond et al had demonstrated that the Quark RMR has good accuracy and consistency 
when compared with the Deltratac ‖TM Figure 2.3 (Blond et al., 2011). The correlation 
has been shown to be good for VCO2 (R2=0.87), VO2 (R2=0.90), and resting metabolic 
rate (RMR) (R2 = 0.90). The correlation and Bland-Altman plot for RMR is shown in 
Figure 2.3.
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Figure 2.3 Correlation and Bland-Altman representation of plot RMR (Blond et al., 
2011) 
 
 
2.7.2 Calculation of substrate oxidation 
Even though the indirect calorimetry technique was primarily developed to measure 
metabolic rate, it was demonstrated some two centuries ago that measurements of 
oxygen consumption, carbon dioxide and nitrogen production can also be used to 
calculate glucose (G) and lipid (L) oxidation rates, respectively (Frayn 1983).  
 
G = 4.55 VCO2 - 3.21 VO2 - 2.87 N 
L = 1.67 (VO2 - VCO2)  - 1.92 N 
 
Data obtained in the first 5 minutes of the measured period was excluded and only 
data obtained during steady state was included. Steady state is defined as less than a 
10% CV in for VO2 and VCO2 (Compher et al., 2006). FiCO2 less than 0.8% or greater 
than 1.0% were excluded to ensure that only optimal measurements of VO2 and VCO2 
were included in the final analysis. The calculated mean values for VO2 and VCO2 were 
used to estimate glucose and lipid oxidation rate. The CV for VO2, VCO2 and RQ were 
5.4%, 5.5% and 2.4%, respectively. Previously validated assumptions on protein 
oxidation were used to calculate energy expenditure and carbohydrate and lipid 
oxidation rates (Wolfe, 1992).  
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2.8 Metabolite and hormone analysis 
Plasma glucose concentration was measured with a Yellow Springs glucose analyser 
(YSI, Ohio, USA) by the glucose oxidase method. The CV of the YSI for measuring 
glucose concentration in a sample taken during the steady state period of the 
hyperinsulinaemic euglycaemic clamp was found to be 1.0%. 
HbA1c was measured by high performance liquid chromatography (Bio-rad): the 
standard error of the mean (SEM) for HbA1c of 5.5%:2.2 and 9.9%:1.6, respectively.  
Plasma insulin concentration was measured with Dako Insulin enzyme linked 
immunoabsorbent assay (DAKO; Denmark) using a spectrophotometric analyser. For 
this method plasma insulin sample is added to a monoclonal anti-insulin antibody 
coated micro-plate well and incubated with anti-insulin conjugate at 20°C - 30°C for 60 
minutes to form an antibody-insulin-conjugate complex. The micro-plate well 
undergoes three automated washes to remove unbound anti-insulin conjugate. 3, 3ꞌ, 
5, 5ꞌ - tetramethylbenzidine (TMB) is then added to the antibody-insulin-conjugate 
complex and incubated at 20°C - 30°C for 10 minutes.  Sulphuric acid is then added to 
stop the reaction between the antibody-insulin-conjugate complex and TMB. The 
change in colour observed after adding sulphuric acid is proportional to the plasma 
insulin concentration and is measured by a spectrophotometer (CV for three mean 
concentrations are as follows: [15.1mU/L:5.6%; 42.1mU/L:6.2%; 153mU/L:9.1%]). 
Plasma glucagon concentration was measured with Millipore Glucagon 
Radioimmunoassay (RIA) kit (Millipore Corporation; Massachusetts SUA), and this 
assay is specific for quantifying pancreatic glucagon. For this method, the kit employs 
labelled tracer antigen (I125 - labelled Glucagon) and Glucagon antiserum to 
determine the glucagon concentration in plasma (CV for three mean concentrations 
are as follows: [82.7.1pg/ml:9.4%; 111.1mU/L:2.9%; 542.6mU/L:3.6%]). 
Plasma NEFA concentration was measured with enzymatic colorimetric method assay 
using the Wako NEFA-HR (2) reagent (Wako Chemical, Neuss Germany) and an 
automated analyser. For this method, plasma NEFA underwent three enzymatic 
reactions, ultimately resulting in a blue purple pigment, the intensity of which is 
proportional to the plasma NEFA concentration, and this is measured by photometric 
means to derive the concentration of NEFA (CV for measurement [range 0.01 - 
4.0mmol/l: ≤1.5%.]). 
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Plasma triglyceride concentration was measured with the Triglyceride GPO-PAP 
spectrophotometric assay (Roche Diagnostics, Germany), using Roche/Hitachi 
MODULARa analyser. For this method triglyceride is hydrolysed by a combination of 
microbial lipases to produce glycerol. Glycerol is phosphorylated and oxidized to 
produce a red dyestuff called chromophore. The plasma triglyceride concentration is 
proportional to the colour intensity of chromophore which is measured by photometric 
means (CV at three mean concentration variety is as follows: [0.81mmol/l:3.7%; 
1.34mmol/l:3.7%; 2.11mmol/l:1.4%]). 
HDL cholesterol concentration was measured by Roche WAKO Direct Homogenous 
assay (SD for measurement [range 0.74-1.76mmol/l:2.7%]). LDL, VLDL and non-HDL 
cholesterol concentrations were calculated from the total and HDL cholesterol 
measurements. 
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2.9 Magnetic resonance methods 
2.9.1 Magnetic resonance spectroscopy (MRS) for measuring glycogen 
concentration 
A magnetic safety check was carried out on every study participant on each scan day, 
immediately prior to the MR scan. All magnetic resonance data were acquired using a 
Philips 3 Tesla Achieva scanner (Philips, Best, The Netherlands). Muscle glycogen 
concentration was obtained using a 6cm diameter 13C surface coil with an integral 1H 
decoupling surface coil (PulseTeq, Worton under Edge, UK). Liver glycogen was 
measured with an in-house built 12cm diameter 13C/1H surface coil. 
 
 
2.9.1.1 Skeletal muscle glycogen measurements 
The subjects were comfortably positioned in the supine position inside the scanner with 
the widest part of the gastrocnemius (calf) muscles lying directly over the RF coil. For 
each study, the coil was held in position against the calf with fabric straps to prevent 
movement. Scout images were obtained at the start of each study to ensure identical 
coil position over the gastrocnemius muscle and also to measure the distance between 
the surface of the coil and the muscle. This distance varied with the amount of 
subcutaneous fat and was used in the calculation of tissue glycogen concentration. 
The amplitude of the glycogen signal measured was determined by tissue glycogen 
concentration and the distance between the coil and muscle.  
13C RF pulse power was calibrated to a nominal value of 80° by observing the power 
dependent variation in signal from a fiducial marker located in the coil housing, 
containing a sample exhibiting 13C signal with short T1 (213mM [2-13C]-acetone and 
25mM GdCl3 in water). In order to ensure that the magnetic field within the scanner 
was uniform over the active volume of the 13C coil, automated shimming was carried 
out by the scanner. The 13C spectra were acquired over 15 minutes using a non-
localised 1H decoupled 13C pulse acquires sequence (TR 120ms, spectral width 8 kHz, 
7000 averages, WALTZ decoupling). 1H decoupling was applied for 60% of the 13C 
signal acquisition, to allow a relatively fast TR of 120ms to be used within scanner 
power Specific Absorption Rate (SAR) limitations.
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2.9.1.2 Liver glycogen measurements 
The subjects were comfortably positioned in the supine position with the 13C liver RF 
coil centrally placed over the right lobe of the liver. While in the scanner, scout images 
were used to confirm correct coil positioning of the liver and measure the distance 
between the coil and liver surfaces. The calibration of pulse power, automated 
shimming and manual coil tuning was carried out. Spectra showing glycogen [1- 13C] 
resonance were acquired over 15 minutes using a non-localised 1H decoupled 13C 
pulse acquired sequence (TR 300ms, spectral width 8kHz, 2504 averages, WALTZ 
decoupling, nominal 13C tip angle of 80°). 
 
 
2.9.1.3 Calibration and analysis of spectra 
13C spectra were calibrated by comparing in vivo [1- 13C] glycogen signal amplitude 
with that obtained from a standard glycogen solution containing 100mM oyster 
glycogen, 70mM potassium chloride and 0.05% sodium azide (Sigma Aldrich Ltd, 
Gillingham, UK). The same coil, tip angles and pulse sequences used to obtain signals 
from in vivo [1- 13C] glycogen were used to obtain signals from the standard glycogen 
solution (Sigma Aldrich Ltd, Gillingham, UK). 
Spectra were analysed with Java Based Magnetic Resonance User Interface (jMRUI) 
version 3.0 and the AMARES algorithm (Naressi et al., 2001) Figure 2.4. Glycogen 
concentration was determined from the magnitude of the natural abundance 13C signal 
from the C1-glycogen carbon at a frequency of 100.3ppm. The signal from the C1 
carbon of glycogen is well separated from signals from other carbon containing 
molecules. For each subject the separation between RF coil and muscle / liver tissue 
was measured from 1H images, and 13C coil loading assessed from 13C flip angle 
calibration data.
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Figure 2.4 A typical 13C spectrum acquired from the calf of a volunteer 
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2.9.2 Measurement of liver and pancreas fat with Three-point Dixon MRI 
A six-channel cardiac coil (Philips Healthcare, Best, the Netherlands) was used to 
measure liver and pancreas triglyceride content. Data were acquired using a three-
point Dixon method (Glover and Schneider, 1991) with three gradient-echo scans  
acquired with adjacent out-of-phase and in-phase echos during a 17 second breath 
hold (repetition time (TR)/echo time /averages/flip angle = 50ms/3.45, 4.60, 
5.75ms/1/5°. A matrix size of 160×109 and field view of 400 - 480mm were deemed 
suitable for volunteer size. This size of matrix enables acquisition of six slices within a 
17 second breath hold, to cover the liver and pancreas with slice thickness of 10mm 
and 5mm, respectively. The fat and water contributions of the MRI signal were 
separated using an in-house programme written in MATLAB, with the triglyceride 
content in the images expressed as a percentage of the total signal from fat and water 
in each pixel. Five liver and two pancreas regions of interest were defined on the fat 
images and their averages were used to estimate intra-organ fat percentage. Using 
the polygon region of interest (ROI) tool in the imaging software Image-J (Abramoff et 
al., 2004) the ROIs were carefully drawn to prevent contamination of data from blood 
vessels, gall bladder or any peripheral tissue so that liver fat data solely represented 
intrahepatic fat. For intra-pancreatic fat analysis, identical ROIs were drawn on both 
fat and water images as demonstrated in Figure 2.5. Again, care was taken to avoid 
contamination from surrounding tissue. The measurements were averaged to calculate 
the triglyceride content in liver and pancreas. The inter-scan Bland–Altman 
repeatability coefficient have previously been reported as 0.5% (Lim et al., 2011a).  
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Figure 2.5 Manually drawn pancreas ROI shown on a BTFE structural scan (left) and 
fat percentage in the MR signal (right) image. The ROI was drawn to avoid 
contamination from surrounding structures
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2.9.3 Measurement of pancreas volume with Balanced Turbo Field Echo 
(BTFE) images 
A new technique to measure pancreas volume with (BTFE) structural scans was 
developed. BTFE images contain both T1 and T2 contrast, which distinguishes high 
signal intensity from vessels and visceral fat with lower intensity signals from the 
pancreas. It can be used to clearly delineate the boundaries of the pancreas from 
adjacent surrounding tissue including the splenic vein, the superior mesenteric 
vessels, the inferior vena cava, the duodenum, and the surrounding visceral fat. 
Twelve axial sections of 5mm thickness were imaged during an eight second breath 
hold (repetition time/echo time/flip angle = 3.1ms/1.6ms/40°, field of view 400 - 
480x300mm according to patient size, zero-filled to give resolution 1.39mm x 1.40mm, 
turbo factor 95, parallel imaging factor 2, bandwidth 1156Hz per pixel). MRIcro 
software was used to convert the images to a format that can be read by Image-J. The 
polygon ROI tool in the freely-available imaging software Image-J (Schneider et al., 
2012) was used to draw regions of interest around the circumference of the pancreatic 
tissue in each slice as demonstrated in Figure 2.6. The sum of the surface areas of 
interest in all the regions of interest was multiplied by the slice thickness of 5mm to 
obtain pancreas volume in mm3. This was then converted to cm3 by dividing by 1000. 
The intra-observer bias (calculated using measurements by a trained researcher) to 
be 0.8cm3 with a 95% limit of agreement of 9.2cm3 (p>0.05) and inter-observer bias 
was 8cm3 with a 95% limit of agreement of 13.1cm3 (p>0.05). Bland-Altman plots for 
20 randomly selected scans for intra-observer and 53 randomly selected scans for 
inter-observer analysis demonstrated reliability of volume measurement Figure 2.7
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Figure 2.6 Demonstrates a BTFE image of the pancreas with a manually drawn ROI 
around the circumference of the pancreas
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Figure 2.7 Bland-Altman plot of intra-observer difference (top) and inter-observer 
difference (bottom) 
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2.9.4 Measurement of skeletal muscle fat with 1H MR spectroscopy 
A 12cm 1H transmitter/receiver coil was used to obtain 1H spectra to measure 
intramyocellular lipid content in muscle Figure 2.8. The PRESS (Point Resolved 
Spectroscopy) (Bottomley, 1987) sequence was used to acquire 1H spectra from the 
gastrocnemius muscle with a  2 × 2 × 2cm voxel, using an echo time of 25ms, spectral 
resolution of 1Hz and repetition time of 5000ms with 32 acquisitions. Spectra were 
analysed with jMRUI version 3.0 using the least square fitting AMARES algorithm 
(Bottomley, 1987; Naressi et al., 2001). The inter-observer bias was 0.09mmol/l with a 
95% limit of agreement of 0.8mmol/l (p>0.05). 
 
 
 
Figure 2.8 Spectral model fitted to a leg muscle 1H spectrum showing calculated IMCL 
and EMCL peaks 
 
 
 
 
 
 
IMCL 
EMCL 
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CHAPTER 3 Evaluating metabolic effects of DDP-4 inhibition in type 2 diabetes  
3.1 Introduction 
Following identification of the therapeutic effect of GLP-1, the DPP-4 inhibitors were 
developed specifically to delay its rapid degradation in plasma and hence enhance the 
incretin effect in type 2 diabetes (Ahren et al., 2005; Mari et al., 2005; Ahren et al., 
2009). Vildagliptin achieves prolonged and almost complete DPP-4 inhibition resulting 
in the extension of meal-induced increases in GLP-1 and GIP over 24 hours. GLP-1 
and GIP increase the sensitivity of the α- and β-cells to glucose, and this is accepted 
as its major mechanism of action (Ahren et al., 2011; JE, 2014). As a result of an 
increase in sensitivity of α cells to glucose, inappropriate glucagon secretion is 
suppressed, and consequently, hepatic gluconeogenesis would be expected to fall 
(Ahren et al., 2010). However, vildagliptin brings about changes that would not be 
predicted from its actions in the pancreas. 
Vildagliptin has been shown to increase glucose utilization as assessed during a two-
step hyperinsulinaemic euglycaemic clamp at the high insulin dose (80mU), and this 
might accompany or underlie an improvement in whole body insulin sensitivity (Ahren 
et al., 2005; Mari et al., 2005; Utzschneider et al., 2009). If peripheral insulin sensitivity 
is increased by vildagliptin, the lower rates of lipolysis in adipose tissue would decrease 
the rate of delivery of non-esterified fatty acids to the liver and muscle, with potential 
decrease in hepatic and muscle triglyceride storage, and consequently improve insulin 
sensitivity in both organs. 
It is known that the increase in fatty acid concentration is associated with a reduction 
in overall glucose utilisation in healthy young glucose tolerant subjects (Thiebaud et 
al., 1982). Additionally lipid accumulation in the liver reduces hepatic insulin sensitivity; 
and in the muscle, it reduces peripheral glucose utilisation, respectively. Pioglitazone 
has been found to reduce fasting and postprandial hepatic glucose production, a 
marker of hepatic insulin sensitivity (Ravikumar et al., 2008). Hepatic insulin sensitivity 
normalised within 7 days of calorie restriction, while peripheral insulin sensitivity 
improved by 36% at 8 weeks (Lim et al., 2011a). The latter suggests that normalization 
of hepatic and peripheral insulin sensitivity may occur at a different time course of a 
therapeutic intervention and this warrants independent assessment. In both these 
studies, the change in hepatic insulin sensitivity was found to be associated with a 
reduction in liver triglyceride content. 
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The effect of vildagliptin on hepatic and peripheral insulin sensitivity has not been 
examined previously. Therefore a randomized, placebo-controlled study was designed 
to examine the possible effects of vildagliptin on these parameters as well as liver 
triglyceride content. In order to minimize any indirect metabolic effects, due to a large 
change in ambient plasma glucose levels, people with type 2 diabetes well controlled 
on metformin alone were studied.  
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3.2 Study design 
3.2.1 Subjects 
44 subjects with well-controlled type 2 diabetes (HbA1c ≤ 7.6% or 60mmol/mol) were 
recruited by newspaper advertisement. All were taking a stable dose of metformin and 
no other oral hypoglycaemic agent or insulin. Inclusion criteria included age 18 - 70 
years; HbA1c ≤ 7.6% or 60mmol/mol; and BMI of 22 - 38kg/m2. Exclusion criteria were 
previous insulin and chronic oral or parenteral steroid therapy; significant ischaemic 
heart disease and cardiac arrhythmia, renal and liver impairment; any acute infection 
which may affect blood glucose control. The main reason for excluding 10 volunteers 
was HbA1c > 7.6% or 60mmol/mol. The characteristics of the study group is 
summarised in Table 3.1, and mean duration of type 2 diabetes was 5.9±0.8years. Age 
and weight were significantly different in the vildagliptin treated and placebo treated 
group by chance. Recruiting via the primary care research network identified 54 
volunteers.  
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 Baseline  
 Vildagliptin 
(n=22) 
Placebo 
(n=22) 
P value 
Age (years) 65.1±0.7 58.7±1.5 0.0004 
Weight (kg) 82.7±3.4 92.1±2.5 0.02 
BMI (kg/m2) 29.4±0.8 30.9±0.6 0.15 
Body fat (%) 31.1±1.8 31.3±1.8 0.92 
Waist hip ratio 0.95±0.02 0.96±0.01 0.68 
FPG (mmol/l) 7.9±0.2 7.5±0.2 0.09 
FPI (mU/L) 12.0±1.6 14.6±2.0 0.47 
HOMA-IR (μU/mol/l3 4.2±0.6 5.0±0.7 0.40 
HbA1c (%) 6.6±0.1 6.5±0.1 0.21 
Non-esterified fatty acid (mmol/l) 0.5±0.03 0.5±0.03 0.76 
 
 
 6 months  
 Vildagliptin 
(n=22) 
Placebo 
(n=22) 
P value 
Age (years) - -  
Weight (kg) 81.2±3.2 91.6±2.6 0.008 
BMI (kg/m2) - -  
Body fat (%) 28.7±1.9 30.0±2.1 0.64 
Waist hip ratio 0.93±0.02 0.96±0.01 0.30 
FPG (mmol/l) 7.0±0.3 7.7±0.4 0.07 
FPI (mU/L) 11.8±1.4 13.2±1.8 0.25 
HOMA-IR (μU/mol/l3 3.7±0.5 4.4±0.6 0.16 
HbA1c (%) 5.9±0.1 6.5±0.1 0.007 
Non-esterified fatty acid (mmol/l) 0.5±0.04 0.5±0.03 0.76 
Table 3.1 Characteristic of study subjects at baseline (top) and at 6 months (bottom) 
Data are shown as mean ± SEM 
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3.2.2 Study protocol 
All subjects were asked to avoid vigorous exercise and take no alcohol for 3 days prior 
to assessment. On the morning of study days, subjects were transported to the study 
centre by taxi, after a 10 hour overnight fast. Only water was allowed during the fasting 
period, and all subjects were advised to omit their morning dose of metformin at 
baseline, and both metformin and either vildagliptin or placebo on subsequent test 
days. Combined metabolic tests with hyperinsulinaemic euglycaemic clamp, 6' 6' - 
dideuterated glucose, and indirect calorimetry were used to measure overall insulin 
sensitivity, endogenous glucose production, and substrate (glucose and lipid) 
oxidation, respectively. The type 2 diabetes subjects were randomised (ratio 1:1) in a 
double-blinded fashion to receive either DPP-4inhibitor (vildagliptin 50mg bid) or 
placebo after completion of baseline studies. The three combined metabolic tests were 
repeated at 6 months. All subjects were asked to maintain their usual calorie intake 
over the 6-month period. Fasting plasma, glucose and insulin were measured monthly 
and Homeostatic Model Assessment of insulin resistance [HOMA-IR] calculated to 
describe month-by-month change in insulin resistance. Fasting plasma non-esterified 
fatty acid was measured at baseline, 1, 3, and 6 months, respectively. Weight was 
measured monthly and body composition was measured at baseline and 6 months 
Figure 3.1. 
Compliance was assessed by pill count and handling of study medication was 
accurately recorded in an accountability ledger. Subjects were given 80 tablets of the 
study medication on each monthly visit and unused tablets were returned, counted and 
recorded on subsequent visits. Compliance was assessed by the difference between 
the number of tablets dispensed and returned.  
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Figure 3.1 Test schedule of type 2 diabetes groups 
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3.3 Side effects of vildagliptin and placebo 
Vildagliptin was well tolerated and there were no meaningful differences between the 
vildagliptin and placebo groups in the overall adverse events (AE) profile. AEs occurred 
in 15 patients (68.2%) in the vildagliptin group vs. 16 patients (72.7%) in the placebo 
group. Discontinuation due to AE happened in one vs. three patients, respectively. 
Serious adverse events (SAEs) (two vs. one patient respectively) were similar between 
the treatment groups with no deaths. Most frequent AEs were of minor infection (four 
vs. five patients) and musculoskeletal disorders (four patients in each group). Mild 
hypoglycaemia (<3.1mmol/l) was reported in one patient in the vildagliptin group and 
none was reported in the placebo group. 
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3.4 Results 
3.4.1 HbA1c and plasma glucose 
Mean HbA1c decreased by 0.5±0.1% (p<0.0001) from a baseline of 6.5±0.1% in the 
vildagliptin group, while a small numerical increase (0.2±0.1% from a baseline of 
6.4±0.1%; p=0.14) was seen in the placebo group figure 3.2 (top). The between-group 
difference in change from baseline was -0.7±0.1% (p<0.001). In the vildagliptin group, 
HbA1c decreased at 3 months (6.1±0.1%; p<0.0001) and at 6 months (6.0±0.1%; 
p<0.0001); whereas in the placebo group there was little change over the entire study 
period (6.4±0.1; p=0.07 at 3 months and 6.5±0.2%; p=0.14 at 6 months, respectively). 
The time course of change is shown in Figure 3.4. 
Mean fasting plasma glucose changed by -0.9±0.3mmol/l (p=0.001) from a baseline of 
7.9±0.2mmol/l in the vildagliptin group and by +0.2±0.3mmol/l (p=0.24) from a baseline 
7.5±0.2mmol/l in the placebo group over the study period figure 3.2 (middle). The 
between-group difference in change from baseline was 1.0±0.5mmol/l (p=0.018). In 
the vildagliptin group a sharp fall in fasting plasma glucose was observed at 1 month 
(7.4±0.3mmol/l; p=0.01) and at 2 months (6.9±0.2mmol/l; p<0.0001). Thereafter fasting 
plasma glucose did not change. In the placebo group, there was a small numerical 
increase in fasting plasma glucose at 3 months (7.6±0.2mmol/l; p=0.34) and at 4 
months (7.7±0.3mmol/l; p=0.11). Thereafter fasting plasma glucose remained 
unchanged. The time course of change is shown in figure 3.3. 
In the vildagliptin treated group, the decrease in fasting plasma glucose positively 
correlated with the decrease in fasting liver triglyceride content at 3 months (r=0.47; 
p=0.02) and 6 months (r=0.44; p=0.03).  
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3.4.2 Plasma insulin  
Mean fasting plasma insulin decreased over 6 months by 0.2±0.2mU/L (p=0.22) in the 
vildagliptin group from a baseline 12.0±1.6mU/L, and by 1.4±0.2mU/L (p=0.21) in the 
placebo group from a baseline of 14.6±2.0mU/L. The between-group difference in 
change from baseline to 6 months was insignificant (p=0.95). Due to the loss of 
samples, subjects with missing data were excluded for further analysis. Complete data 
sets for 11 and 18 subjects in the vildagliptin and placebo treated groups respectively 
and 14 control subjects were analysed to compare the difference in fasting insulin 
concentration over 6 months. There was a significant difference in mean fasting insulin 
concentration at the p<0.05 level for the vildagliptin, placebo and control groups [F (2, 
6) = 56.8, p<0.0001]. Figure 3.2 shows fasting plasma insulin concentration in all (left) 
and complete (right) data sets in all groups, over 6 months.  
 
 
 
Figure 3.2 Fasting insulin concentration in the all (left) and complete (right) data sets 
in all groups
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3.4.3 Plasma non-esterified fatty acid 
Plasma NEFA remained unchanged over the study period in the vildagliptin (0.48±0.04 
to 0.50±0.05mmol/l; p>0.05) and placebo (0.50±0.03 to 0.49±0.03mmol/l; p>0.05) 
groups. 
 
 
3.4.4 Whole body insulin sensitivity assessed by euglycaemic (5.5mmol/l) 
hyperinsulinaemic (40mU insulin min-2min-1) clamp 
Baseline mean glucose disposal rates were 3.24±0.30mg/kg/min in the vildagliptin 
group and 3.19±0.38mg/kg/min in the placebo group. Glucose disposal rates did not 
change meaningfully in either group from baseline to 6 months (3.24±0.30 to 
3.50±0.31mg/kg/min and 3.19±0.38 to 3.52±0.40mg/kg/min, respectively) Figure 3.3 
(bottom). There was no between-group difference in the change from baseline (-
0.06mg/kg/min; p=0.86).  When glucose disposal was expressed as a ratio to the 
clamp plasma insulin at steady state [M/I (ml/kg/min/pM)], insulin sensitivity did not 
change at 6 months in the vildagliptin (0.0065±0.0006 to 0.0071±0.0006ml/kg/min/pM) 
and placebo group (0.0074±0.0013 to 0.0078±0.0013ml/kg/min/pM). There was no 
between-group difference in the change from baseline (0.0001ml/kg/min/pM; p=0.89). 
 
 
3.4.5 Hepatic glucose production (HGP) 
Baseline fasting hepatic glucose production was the same in the vildagliptin and 
placebo group (1.95±0.10 vs. 1.95±0.07mg/kg/min). At 6 months, fasting hepatic 
glucose production was similar in both groups (1.97±0.1 vs. 2.01±0.1mg/kg/min; 
p=0.37). Baseline clamp hepatic glucose production was comparable between the 
vildagliptin and placebo groups (1.13±0.1 vs. 0.94±0.1mg/kg/min; p=0.16). At 6 
months, clamp hepatic glucose production was also comparable between the two 
groups (1.16±0.1 vs. 1.03±0.1 mg/kg/min; p=0.09). Percentage suppression of HGP 
during the hyperinsulinaemic euglycaemic clamp at baseline and 6 months was similar 
in the vildagliptin (42.2±0.07 vs. 42.8±0.05%; p=0.89) and placebo group (54.7±0.06% 
vs. 48.4±0.07%; p=0.42). 
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Figure 3.3 Change in HbA1c (top), fasting plasma glucose (middle) and whole body 
insulin sensitivity (bottom) at baseline and 6 months
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Figure 3.4 The effect of 6 months of vildagliptin on change in HbA1c (%) (left)  and 
fasting plasma glucose (FPG) (mmol/l) (right) in the vildagliptin treated and placebo 
groups, respectively  
 
 
3.4.6 Whole body glucose and lipid oxidation 
Fasting whole body glucose oxidation rate did not differ between the vildagliptin and 
placebo groups either at baseline (0.99±0.16 vs. 0.87±0.10mg/kg/min) or at 6 months 
(0.77±0.19 vs. 0.95±0.14mg/kg/min), respectively. The between-group difference in 
change from baseline was insignificant; p=0.21. Similarly, insulin stimulated whole 
body glucose oxidation rate did not differ between the vildagliptin and placebo groups 
at baseline (1.52±0.21 vs. 1.50±0.08mg/kg/min) or at the end of the study (1.55±0.16 
vs. 1.65±0.14mg/kg/min), respectively. The between-group change from baseline was 
insignificant; p=0.65. 
Fasting whole body lipid oxidation rate did not differ between the vildagliptin and 
placebo groups either at baseline (1.08±0.07 vs. 1.13±0.05mg/kg/min) or at study 
endpoint (1.13±0.06 vs. 1.05±0.08mg/kg/min), respectively. There was no significant 
difference in clamp lipid oxidation between both groups at baseline (0.89±0.09 vs. 
0.86±0.08mg/kg/min) and end of study (0.91±0.07 vs. 0.94±0.07mg/kg/min). 
Fasting whole body energy expenditure did not change in the vildagliptin (1698±92.5 
vs. 1673±89.6kcal/day; p=0.35) or placebo groups (1849±75.3 vs. 1729±94.9kcal/day; 
p=0.08) over 6 months. No change was observed in clamp whole body energy 
expenditure in both vildagliptin (1724±77.6 vs. 1676±104.8kcal/day; p=0.22) and 
placebo group (1877±96.9 vs. 1798±101kcal/day; p=0.23).
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3.4.7 HOMA-IR 
There was a numerical decrease in mean HOMA-IR over 6 months by 
0.7±0.5μU/mol/l3; p=0.22 in the vildagliptin group from a baseline of 4.2±0.6μU/mol/l3, 
and by 0.3±0.5μU/mol/l3; p=0.21 in the placebo group from a baseline of 
5.0±0.7μU/mol/l3. The between-group difference in change from baseline to endpoint 
was insignificant (p=0.54). Due to the loss of samples, subjects with missing data were 
excluded for further analysis. Complete data sets for 12 and 18 subjects in the 
vildagliptin and placebo treated groups respectively and 14 control subjects were 
analysed to compare the difference in HOMA-IR over 6 months. There was a significant 
difference in mean HOMA-IR at the p<0.05 level for the vildagliptin, placebo and control 
groups [F (2, 6) = 62.1, p=0.0001]. Figure 3.5 shows HOMA-IR in all (left) and complete 
(right) data sets in all groups, over 6 months. 
 
 
 
Figure 3.5 HOMA-IR in all (left) and complete (right) data sets in all groups 
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3.5 Discussion 
The data demonstrate that DPP-4 inhibition can bring about clinically useful decreases 
in HbA1c, fasting plasma glucose and insulin concentration in the patient group studied. 
Even though the patient group had well controlled type 2 diabetes and change in 
plasma glucose levels was expected to be modest, HbA1c fell from an average of 6.5% 
to 6.0% in the group receiving vildagliptin, and 70% achieved a normal HbA1c (<6.1% 
or 43mmol/mol). However, there was no change in whole body insulin sensitivity as 
assessed by the euglycaemic (5.5mmol/l) hyperinsulinaemic (40mU insulin min-2min-
1). Additionally, there was no change in hepatic glucose production, which is a marker 
of hepatic insulin sensitivity. 
Overall, blood glucose control improved on vildagliptin as reflected by mean HbA1c 
falling into the non-diabetic range and mean fasting plasma glucose falling by 
0.9mmol/l at 6 months. These results are particularly remarkable given the very low 
baseline HbA1c of patients included in the study (mean 6.4%) and considering that oral 
hypoglycaemic agents in general have effects directly proportional to initial blood 
glucose levels. Mean HbA1c was normalized following 6 months of treatment with 
vildagliptin 50mg bid (twice daily). Of note, the vildagliptin treatment effect on HbA1c 
seen in this study is very robust when compared to previous data (Scherbaum et al., 
2008). In the present study, vildagliptin was added to stable metformin therapy and it 
is possible that this is relevant to the extent of normalization of blood glucose levels.  
Although overall insulin sensitivity assessed by euglycaemic (5.5mmol/l) 
hyperinsulinaemic (40mU insulin min-2min-1) clamp did not change with 6 months of 
vildagliptin, insulin resistance assessed by HOMA-IR improved with vildagliptin 
treatment. A significant change in HOMA-IR was observed as early as the second 
month, and reached nadir at 4 months of vildagliptin treatment. In a recent, larger 
study, a significant reduction in HOMA-IR was observed at 9 months (Derosa et al., 
2013). In the later study, the baseline HbA1c was higher when compared to this study 
group (8.1%); and this may account for the time difference in which significant 
reduction in HOMA-IR is achieved. 
Basal hepatic glucose production did not change with vildagliptin treatment and this 
confirms previous observations with both vildagliptin and sitagliptin therapy (Azuma et 
al., 2008; Solis-Herrera et al., 2013). In contrast, in a single dose, post-meal and 
overnight study (Balas et al., 2007), there was on average 0.3mg/kg/min less hepatic 
glucose production in the vildagliptin group relative to the placebo group from the 
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beginning of the dinner meal until the next morning. This contrasting result suggests 
that the effect of DPP-4 inhibition on the suppression of fasting hepatic glucose 
production differs from the suppression of postmeal hepatic glucose production. In the 
later study (Balas et al., 2007), it is possible that maximal post meal concentration of 
GLP-1 and GIP preserved by vildagliptin enhanced the suppression of inappropriate 
glucagon secretion. In the fasting state, GLP-1 and GIP concentration is expected to 
be low and the incretin effect on glucagon suppression is negligible. Further work is 
required to evaluate the effect of vildagliptin on hepatic glucose production during low, 
physiological increase in insulin concentrations such as occurs after meals. The lack 
of improvement in fasting hepatic glucose production despite fall in liver fat (chapter 4) 
must be considered. This may relate to the very well controlled type 2 diabetes subjects 
under study, as hepatic glucose production in diabetes has been observed to decline 
to non-diabetic levels below a plasma glucose of approximately 8mmol/l (DeFronzo et 
al., 1989). Also it must be noted that the clamp insulin levels were optimal to measure 
peripheral rather than hepatic insulin sensitivity. Although, ideally a two-step clamp 
would have been used with an initial low dose insulin concentration, this was not 
feasible in view of the duration of the studies and the number of test visits required of 
the subjects. 
Treatment with vildagliptin added to metformin over 6 months resulted in a 1.6kg weight 
loss vs. baseline. While overall, treatment with DPP-4 inhibitors is weight neutral, it 
was previously reported that from a similarly low baseline level of glycaemia as in the 
present study (Scherbaum et al., 2008), baseline mean HbA1c 6.6%) vildagliptin 
therapy reduced body weight by 1.1kg over a 2 year period (Bluher et al., 2014). 
Furthermore, examination of weight as a function of fasting plasma glucose in a pooled 
analysis of more than 2000 patients demonstrated that negative calorie balance 
occurred in those with glucose levels below the renal threshold (Bluher et al., 2014). 
De novo lipogenesis was not assessed in this study, but overall a modest increase in 
this process is unlikely to account for the lower plasma glucose levels in the face of no 
decrease in hepatic glucose production. In this study, clamp lipid oxidation did not 
change with vildagliptin treatment. Hepatic export of lipid has to be considered. This is 
unlikely in view of the results on total hepatic lipid content presented in chapter 4 and 
the results from a previous study showed no effect of vildagliptin treatment on 
postprandial triglyceride levels secondary to reduced flux of lipoproteins from the liver 
73 
 
(Matikainen et al., 2006). The fall in fasting plasma glucose is likely to reflect the 
prolonged effect of glucagon suppression during an overnight fast. 
Possible limitations of the study must be considered. Examination of whole body insulin 
sensitivity by conducting euglycaemic hyperinsulinaemic clamp at a range of insulin 
concentrations would have been ideal. Similarly, detailed examination of hepatic 
insulin sensitivity within the physiological range of insulin concentrations would be of 
interest in relation to the substantial decrease in hepatic triglyceride. Data for whole 
body glucose and lipid oxidation rates measured by indirect calorimetry was collected 
for 11 and 8 subjects in the vildagliptin treated and placebo groups, respectively. 
Technical problems prevented more subjects being studied and therefore the small 
numbers in each group lacked the power required to detect any true difference. 
In summary, the study has demonstrated that a clinically significant reduction in fasting 
glucose, insulin and HbA1c in well controlled type 2 diabetes is achieved on vildagliptin 
therapy. No effect of the drug on hepatic glucose production could be detected. 
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CHAPTER 4  Effect of vildagliptin on liver steatosis and muscle lipid content  
4.1 Introduction 
Lipid toxicity has been identified as a major contributing factor to insulin resistance 
(Lee et al., 1994a; McGarry, 2002). Human studies have demonstrated the association 
between hepatic lipid accumulation and insulin resistance in subjects with metabolic 
syndrome (Kotronen et al., 2008). This concept is supported by the observance of 
increased prevalence of type 2 diabetes in people with NAFLD (Shibata et al., 2007). 
Hepatic lipid accumulation reduces insulin sensitivity, impairs glucose uptake, 
glycogen synthesis, and increases gluconeogenesis in the liver (Samuel et al., 2004). 
The latter contributes to inadequate suppression of hepatic glucose suppression, 
which results in fasting hyperglycaemia. 
In normal health, acute rises in plasma free fatty acid concentration have been shown 
to increase intramyocellular lipid content (IMCL) (Boden et al., 2001), which is a marker 
for muscle insulin resistance. IMCL accumulation is now known to be associated with 
impaired skeletal muscle insulin sensitivity in normal glucose tolerance subjects 
(Krssak et al., 1999), lean off-spring of type 2 diabetes (Jacob et al., 1999) and also 
obese type 2 diabetes subjects (Ravikumar et al., 2008). Additionally, hyperlipidaemia 
has been shown to reduce insulin stimulated glucose disposal in skeletal muscle during 
hyperinsulinaemic euglycaemic clamp (Johnson et al., 1992; Kelley et al., 1993). In a 
recent study, calorie restriction using a 600kcal diet has been shown to reduce liver 
triglyceride concentration by 30% in 7 days and normalise hepatic glucose production 
(Lim 2011).  
As such, the effect of new therapeutic strategies on liver and muscle lipid content 
warrant further investigation. Although DDP-4 inhibitors were developed to delay the 
rapid degradation of GLP-1 and GIP, vildagliptin brings about changes that would not 
be predicted from its actions in the pancreas. It decreases postprandial triglyceride 
levels and decreases lipolysis as assessed in vivo by palmitate dilution more than can 
be accounted for by change in plasma insulin concentration (Matikainen et al., 2006; 
Derosa et al., 2014). This could result in a decrease in liver triglyceride concentration. 
Vildagliptin has also been shown to increase glucose utilization as assessed during a 
two-step hyperinsulinaemic euglycaemic clamp at the high insulin dose (80mU) and 
this might accompany or underlie a reduction in liver triglyceride concentration (Ahren 
et al., 2005; Mari et al., 2005; Utzschneider et al., 2009). If peripheral insulin sensitivity 
is increased by vildagliptin, the lower rates of lipolysis in adipose tissue would decrease 
75 
 
the rate of delivery of non-esterified fatty acids to the liver with potential decrease in 
hepatic triglyceride storage.  
Whether hepatic lipid metabolism is specifically affected has not previously been 
examined and there is no information on any modulation of liver triglyceride 
concentration. The randomized placebo-controlled study was designed to examine the 
possible effects of vildagliptin on liver and muscle triglyceride content in a group of 
individuals with type 2 diabetes subjects well controlled on metformin alone. In order 
to minimise any indirect effect due to a large change in ambient plasma glucose levels, 
well controlled type 2 diabetes subjects on metformin alone were studied. 
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4.2 Study design 
4.2.1 Subjects  
The 44 (28M; 16F) well controlled type 2 diabetes subjects were as previously 
described in CHAPTER 3. In order to assess the extent of any normalization of the 
parameters measured, a control group of subjects with normal glucose tolerance was 
recruited. The characteristics for the groups is summarised in Table 4.1. The study was 
approved by the Newcastle and North Tyneside 2 Research Ethics Committee. 
 
 
 Vildagliptin 
(n=22) 
Placebo 
(n=22) 
Type 2 
Diabetes 
group (n=44) 
Controls 
(n=14) 
Age (years) 65.2±0.7 58.9±1.6 61.8 ± 1.0 59.0 ± 2.2 
Weight (kg) 83.0±3.2 91.8±2.4 87.7 ± 2.1 86.7 ± 3.7 
BMI (kg/m2) 29.4±0.8 31.1±0.6 30.0 ± 0.5 29.6 ± 1.0 
Body fat (%) 31.5±1.6 30.7±1.8 31.6 ± 1.2 27.9 ± 2.6 
WHR 0.95±0.01 0.95±0.01 0.95 ± 0.01 0.9 ± 0.02* 
FPG (mmol/l) 7.7±0.2 7.8±0.3 7.7 ± 0.2 5.1± 0.1** 
FPI (mUlL) 13.0±1.8 14.8±1.6 13.8 ± 1.2 7.9 ± 0.9** 
HOMA-IR 
(μU/mol/l3) 
4.4±0.6 5.3±0.7 5.0 ± 0.4 1.9 ± 0.2** 
 
HbA1c (%) 
(mmol/mol) 
6.6±0.1 6.5±0.09 6.4 ± 0.07 
(46.5 ± 0.8) 
 
Table 4.1 Characteristics of study groups 
Data are shown as mean ± SEM. *P ≤ 0.05 and **P ≤ 0.01 
 
 
4.2.2 Study protocol 
The study protocol is described in CHAPTER 3. MR studies were carried out at 
baseline, and then at 1, 3, and 6 months of drug or placebo treatment. 
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4.3 Results 
4.3.1 Liver triglyceride 
At baseline, liver triglyceride was higher in the whole type 2 diabetes group compared 
with the control group (6.7±0.7 vs. 3.4±0.8%; p=0.0008). Mean fasting liver triglyceride 
decreased during vildagliptin treatment from 7.3±1.0% at baseline to 5.3±0.9% at 6 
months (p=0.001). There was no change in the control group (5.4±0.7% to 5.4±1.0%; 
p=0.48). The between-group difference in change from baseline was significant 
(p=0.013), representing a clinically relevant improvement in liver triglyceride. The time 
course of change is shown in Figure 4.1. Within the vildagliptin treated group, liver 
triglyceride fell from baseline by 12% at 1 month (p=0.04), 29% at 3 months (p=0.001) 
and 27% at 6 months (p=0.0006). In the placebo group intra-hepatic triglyceride 
remained unchanged over 6 months (6.0±0.9 to 5.7±1.0%; p=0.96).  
 
 
 
Figure 4.1 The effect of 6 months of vildagliptin on change in (left) liver triglyceride 
(TG) content (expressed as absolute change in the percent hepatic fat, not relative 
change and (right) fasting plasma glucose in the vildagliptin treated and placebo 
groups, respectively (*p<0.05; **p<0.005; ***p<0.0005)
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4.3.2 Plasma alanine aminotransferase (ALT) 
Mean plasma ALT fell from 27.2±2.8 to 20.3±1.4IU/l in the vildagliptin treated group 
(p=0.0007) and did not change in the placebo group (29.6±3.0 to 29.6±3.7IU/l; p=0.44). 
There was a positive correlation between the fall in ALT and the fall in liver triglyceride 
in the vildagliptin treated group (r=0.83; p<0.0001) Figure 4.2. The correlation between 
these remained significant even if the outlier was excluded (r=0.64; p=0.003). 
 
 
 
Figure 4.2 Relationship between change in liver triglyceride concentration and change 
in plasma ALT (r=0.83; p<0.0001). The correlation remained significant if the outlying 
point was excluded (r=0.64; p=0.003)
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4.3.3 IMCL 
At baseline IMCL was higher in the type 2 diabetes compared with the control group 
(22.3±2.0 vs. 16.2±1.1mmol/l; p=0.006). Due to the difficulty in analysing IMCL data, 
subjects with missing data were excluded for further analysis. Complete data sets for 
15 and 10 subjects in the vildagliptin and placebo treated groups respectively and 10 
subjects in the control group. There was a significant difference in the effect of 
vildagliptin on IMCL at the p<0.05 level for the vildagliptin, placebo and control groups 
[F (2, 3) = 18.5, p=0.02]. Figure 4.3 shows IMCL in all (left) and complete (right) data 
sets in all groups, over 6 months.  
 
 
 
Figure 4.3 IMCL in all (left) and complete (right data sets in all groups
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4.3.4 Fasting lipid parameters  
Although there was a tendency for fasting triglyceride and total cholesterol to decrease 
with vildagliptin treatment in comparison with the placebo group, there was no between 
group difference in mean change. Fasting lipid parameters are summarized in Table 
4.2 with p values for adjusted mean change. 
 
 
 Vildagliptin Placebo p value  
Baseline Endpoint Baseline Endpoint 
Triglyceride 1.5±0.1 1.3±0.1 1.4±0.1 1.4±0.1 0.17 
Total cholesterol 4.2±0.2 3.9±0.2 4.2±0.2 4.2±0.2 0.57 
LDL cholesterol 2.1±0.2 1.9±0.2 2.3±0.3 2.1±0.2 0.72 
HDL cholesterol, 1.4±0.1 1.4±0.1 1.3±0.1 1.3±0.1 0.37 
Non-HDL cholesterol 2.8±0.2 2.5±0.2 2.9±0.2 2.7±0.2 0.34 
VLDL cholesterol 0.5±0.1 0.4±0.0 0.5±0.0 0.4±0.0 0.99 
Non-esterified fatty 
acid 
0.5±0.0 0.5±0.0 0.5±0.0 0.5±0.0 0.63 
Table 4.2 Fasting lipid parameters with p values for adjusted mean change 
Data are shown as mean ± SEM. *P ≤ 0.05 and **P ≤ 0.01 
 
 
4.3.5 Weight 
Mean body weight decreased by 1.6±0.5kg from a baseline of 82±3.4kg (p=0.002) in 
the vildagliptin group and by 0.4±0.5kg from a baseline of 92.1±2.5kg (p=0.41) in the 
placebo group over the study period. The between-group difference did not reach 
statistical significance (p=0.08). Modest weight loss in the placebo group was 
associated with no change in liver triglyceride content, and the time course of change 
in weight and change in liver triglyceride content were not congruent in either group, 
Figure 4.4.
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Figure 4.4 The relationship between change in liver triglyceride (fat%) and change in 
weight (kg) for each individual is shown for the vildagliptin (left hand column) and 
placebo (right hand column) at 1 months (top row), 3 months (middle row) and 6 
months (bottom row)
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4.4 Discussion 
This study demonstrates for the first time that DPP-4 inhibition can bring about clinically 
useful decreases intra-hepatic triglyceride levels associated with a fall in plasma ALT 
and plasma glucose. The improvement in glucose control observed is unlikely to have 
had a direct effect upon liver triglyceride levels as shown by observation of no change 
in liver triglyceride levels during metformin or sulfonylurea therapy (Tiikkainen et al., 
2004; Phielix et al., 2013). 
The mechanism underlying both the discovery and development of DPP-4 inhibitors 
was the GLP-1 mediated enhancement of pancreatic islet function (Ahren et al., 2005; 
Mari et al., 2005; Ahren et al., 2009). The GLP-1 mediated action brings about 
increased sensitivity of both α- and β-cells to glucose. However vildagliptin has been 
observed to cause changes, which suggest additional metabolic effects. These include 
decreases in rate of appearance of palmitate (i.e. lipolysis) and decreases in lipid 
oxidation rate during a euglycaemic clamp study (Azuma et al., 2008). During fasting, 
almost 80% of fatty acid in the very low-density lipoprotein secreted from the liver 
derives from adipose tissue (Barrows and Parks, 2006). The rate of de novo 
lipogenesis rises sharply with increasing extent of liver triglyceride accumulation and 
accounts for over three-fold greater contribution to plasma triglyceride in subjects with 
non-alcoholic fatty liver disease (Lambert et al., 2014).  
It was therefore important to quantify the effect of DPP-4 inhibition upon ectopic 
triglyceride in liver, as this organ is central to lipoprotein homeostasis and whole body 
lipid metabolism.  
The present study has demonstrated a substantial fall in fasting liver triglyceride (fat 
percentage) concentration during vildagliptin treatment, with levels becoming similar to 
that of the non-diabetic control group. The major influence on liver triglyceride is body 
weight; and weight and per cent body fat decreased to only a modest degree in the 
vildagliptin treated group. Figure 4.5 illustrates the lack of temporal relationship 
between change in body weight and change in liver triglyceride (fat percentage). 
Additionally, by applying the observation of Tiikkainen and colleagues that a 1kg loss 
of body weight at steady state is associated with a decrease in liver triglyceride (fat 
percentage) of approximately 0.58% (Tiikkainen et al., 2003), the highly statistically 
significant fall in liver triglyceride on vildagliptin therapy remained (1 month p<0.01; 3 
months p<0.01; 6 months p<0.001). The Tiikkainen correction was calculated as the 
product of change weight and correction factor (0.58), added to liver fat percentage (if 
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weight increased) or subtracted from liver fat percentage if weight decreased at that 
time point. The extent of the fall in liver triglyceride was clinically significant as reflected 
by the reduction in plasma ALT and also by the correlations between the decreases in 
liver triglyceride and those of both plasma ALT and fasting plasma glucose. Compared 
to the 50% reduction in liver triglyceride reported for thiazolidinedione therapy (Bajaj et 
al., 2003; Ravikumar et al., 2008), a 27% reduction was seen in the vildagliptin treated 
group and there was no change in the placebo treated group. However, when the 
analysis is restricted to those individuals who completed 6 months of vildagliptin 
therapy, intra-hepatic triglyceride fell by 42% (p=0.0003). 
The mechanism underlying the fall in liver triglyceride on vildagliptin therapy must be 
considered. Either fat oxidation must have increased or the balance between net 
hepatic storage and export must have changed. The most likely explanation is a 
substantial decrease in storage due to the previously observed decrease in fasting 
lipolysis and fatty acid supply to the liver (Utzschneider et al., 2009). De novo 
lipogenesis was not assessed in this study, but overall a modest increase in this 
process would account for the lower plasma glucose levels in the face of no decrease 
in hepatic glucose production and still be consistent with the observed change in 
hepatic triglyceride concentration. No change in whole body lipid oxidation was 
observed. Hepatic export of lipid is unlikely to have increased given the 13% fall in 
plasma triglyceride concentration and given the results from a previous study which 
showed no effect of vildagliptin treatment on postprandial triglyceride levels secondary 
to reduced flux of lipoproteins from the liver (Matikainen et al., 2006). 
It is known that the GLP-1 receptor is expressed on human hepatocytes (Svegliati-
Baroni et al., 2011) and a direct effect of increased GLP-1 levels is feasible. GLP-1 
agonist therapy is known to decrease hepatic triglyceride levels in ob/ob mice (Gupta 
et al., 2010) and DPP-4 inhibitors have been shown to reduce liver fat in obese mice 
models (Kern et al., 2012). Furthermore, DPP-4 inhibition prevents fatty liver 
developing during overfeeding of both wild type and glucokinase deficient mice 
(Shirakawa et al., 2011). In the latter study it was also demonstrated that fatty acid 
synthase expression was decreased. However, caution is required in drawing 
mechanistic information from studies on rodents which, unlike humans, are able to 
synthesize fatty acids from glucose in adipocytes (Shrago et al., 1969). 
Although there was a tendency for intramyocellular lipid to decrease with vildagliptin 
treatment, this was not statistically significant. Metformin and pioglitazone have been 
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shown to reduce intramyocellular lipid by 25% and up to 55%, respectively (Teranishi 
et al., 2007; Ravikumar et al., 2008). The exact mechanism through which 
intramyocellular lipid accumulation impairs skeletal muscle insulin sensitivity is not fully 
understood. Nonetheless, it has been suggested that the intermediaries of lipid 
oxidation such as DAG, ceramide and sphingosine (Samuel et al., 2010; Dube et al., 
2011) may play a role in the impairment of GLUT 4 expression and insulin signalling 
(Greco et al., 2002). Even though elevated intramyocellular lipid in endurance-trained 
athletes was found to be associated with an increase in muscle insulin sensitivity 
(Goodpaster et al., 2001), intramyocellular lipid oxidative capacity is higher in 
endurance-trained athletes compared to lean sedentary control subjects (Goodpaster 
et al., 2001; Perseghin et al., 2002). This suggests that intramyocellular lipid oxidative 
capacity may also contribute significantly to normal muscle insulin sensitivity. Arguably 
it should be considered whether either reducing intramyocellular lipid accumulation or 
increasing oxidative reduction could increase muscle insulin sensitivity. Short-term low 
calorie diet has been shown to decrease IMCL by increasing its rate of oxidation. This 
led to improving skeletal muscle insulin sensitivity (Lara-Castro et al., 2008).  
The starting mean hepatic triglyceride level in the vildagliptin treated group was by 
random chance higher than that of the placebo group. It is therefore important to be 
sure that the observed change was not merely tendency to the mean. To exclude this 
possibility, when subjects were pair matched between the groups for baseline liver 
triglyceride level with values within 0.2%, 12 pairs were identified. In the vildagliptin 
treated subjects liver triglyceride levels fell over the 6-month period (6.3±1.0 to 
4.1±0.6%; p<0.02) whereas there was no change in the pair members on placebo 
(6.4±1.0 to 6.6±1.6%; p=0.73).  
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Figure 4.5 Lack of relationship between change in liver fat and change in weight for 
the placebo group (left) and the vildagliptin (right) 
 
 
Weight loss of 0.5kg brought about no change in liver fat in the placebo group whereas 
the continuing steady weight loss in the vildagliptin group brought about no additional 
change in liver fat from 3 to 6 months. 
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CHAPTER 5 Morphology and composition of the pancreas  
5.1 Introduction  
Three basic aspects of the pancreas may be of relevance to the aetiopathogenesis of 
type 2 diabetes. Firstly, the overall size of the pancreas must be considered. By the 
time type 2 diabetes is diagnosed, the number of β cells would have decreased by 
50% (Butler et al., 2003; Rahier et al., 2008). Studies using ultrasound or CT have 
suggested 7 - 22% decrease in pancreas volume (Alzaid et al., 1993; Saisho et al., 
2007), but the groups studied have not been homogenous. Secondly, there has been 
no description of the overall appearance of the pancreas in type 2 diabetes. There is 
marked variation of morphology in the general population, with a more serrated 
boundary of the pancreas generally ascribed to ageing (Hahn, 1999). Thirdly, the 
pancreas triglyceride content has been reported to be related to β cell function 
(Tushuizen et al., 2008; Szczepaniak et al., 2012).  
Short-term exposure of fatty acid to normal islet cell cultures has been found to 
increase glucose stimulated insulin secretion (Gravena et al., 2002), and long-term 
exposure of fatty acid to normal islet cell cultures have been reported to have a 
contrasting effect (Dubois et al., 2004). Both effects were thought to be independent 
of glucose concentration. However, long-term exposure of the pancreas to lipids 
facilitates intra-pancreatic lipid accumulation, and this may possibly be related to loss 
in first phase glucose stimulation insulin response (Lee et al., 1994a; Lupi et al., 2002a) 
and β cell apoptosis (Shimabukuro et al., 1998b; Butler et al., 2010). Measurement of 
pancreas fat content using magnetic resonance spectroscopy has been questioned 
(Saisho et al., 2008). Spectroscopy requires pre-definition of the volume of tissue but 
the organ moves with respiration. To avoid possible inclusion of signal from 
surrounding adipose tissue, an imaging-based method of high precision (Lim et al., 
2011a) was developed. Using this method during rapid weight loss, the pancreas fat 
content was shown to decrease over the same time course of return of normal insulin 
secretory capacity (Lim et al., 2011a). That longitudinal study was designed to evaluate 
the mechanisms underlying the return to normal glucose control during a very low 
calorie diet and was not large enough to quantitate precisely the difference in pancreas 
morphology between type 2 diabetes and age, weight and sex matched non-diabetic 
controls.  
The present study was designed to define volume, morphology and triglyceride content 
of the pancreas. As DPP-4 inhibition may delay the decline in insulin secretion, and as 
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this may underlie atrophy of the pancreas, the possible effects of vildagliptin on 
pancreas volume in type 2 diabetes were determined during the course of 6 months of 
therapy. 
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5.2 Study design 
5.2.1 Subjects 
The clinical and metabolic descriptions of type 2 diabetes subjects are given in 
CHAPTER 3. Fourteen (8M: 6F) normal glucose tolerant subjects matched for age, 
weight and BMI, with no first - degree relative of diabetes were recruited as controls 
and studied only at baseline to provide comparative data. They were not on any drug 
therapy affecting glucose metabolism such as oral steroids and had no known first - 
degree relative with diabetes. The characteristics of both type 2 diabetes and control 
groups is summarised in Table 5.1.  
 
 
 Type 2 
diabetes 
(n=42) 
Controls 
(n=14) 
p value 
Weight (kg) 87.2±2.0 86.7±3.7 0.81 
BMI (kg/m2) 30.3±0.5 29.6±1.0 0.67 
Body fat (%) 31.6±1.2 27.9±2.6 0.11 
Waist/Hip ratio  0.95±0.01 0.90±0.02 0.02 
Age (years) 61.8±1.0 59.0±2.2 0.10 
Fasting plasma glucose (mmol/l) 7.9±0.5 5.1±0.1 <0.0001 
Fasting plasma insulin (mU/L) 13.3±1.3 7.9±0.9 0.002 
HOMA-β (%) 72.0±7.1 97.3± 9.5 0.01 
HOMA-IR (μU/mol/l3) 4.7±0.4 1.9 ± 0.2 0.02 
HbA1c (% ) 6.4±0.1  -  
Duration of diabetes (years) 5.7±0.7 -  
Table 5.1 Anthropometry and metabolic characteristics of the type 2 diabetes and 
control groups 
Data are shown as mean ± SEM 
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5.2.2 Study protocol  
A non-invasive magnetic resonance method was developed to quantitate pancreas 
volume using Balanced Turbo Field Echo (BTFE) structural scans.  BTFE images 
contain a mix of T1 and T2 contrast, which distinguishes high signal intensity from 
vessels and visceral fat with lower intensity signals from the pancreas. It can therefore 
be used to clearly delineate the boundaries of the pancreas from the adjacent 
structures, including the surrounding visceral fat, the splenic vein, the superior 
mesenteric vessels, the inferior vena cava and the duodenum.  Twelve axial sections 
of 5mm thickness were imaged during an 8 second breath hold (repetition time/echo 
time/flip angle = 3.1ms/1.6ms/40°, field of view 400 - 480x300mm according to patient 
size, zero-filled to give resolution 1.39mm x 1.40mm, turbo factor 95, parallel imaging 
factor 2, bandwidth 1156Hz per pixel). The polygon ROI tool in the freely-available 
imaging software Image-J (Schneider et al., 2012) was used to delineate the 
pancreatic tissue in each section. Integration over all the sections containing tissue 
allows the total pancreas volume in cm3 to be obtained. A Bland-Altman analysis was 
carried out to define repeatability and reproducibility of the pancreas volume 
measurement, with independent inter-observer assessment of pancreas volume 
performed by two trained analysts (myself and another trained observer). A subset of 
20 randomly selected measurements were analysed twice to define inter-observer 
statistics. 
A pancreas volume index, defined as the pancreas volume in cm3 divided by the body 
surface area calculated by the method of Dubois and Dubois (DuBOIS and DuBOIS, 
1916)  was used to examine possible effects of different anthropometry on observed 
measurements (Goda et al., 2001). The ratio of the pancreas volume to the waist 
circumference (in cm3/cm) was also calculated to evaluate the data corrected for 
potential excess visceral fat in type 2 diabetes subjects.  
The anterior border of the pancreas was observed to be particularly variable in respect 
of degree of smoothness or irregularity. To quantify this, a five point semi-quantitative 
scale of irregularity (1 = most irregular, 5 = least irregular) using standardized outlines 
to define each grade was applied to score all pancreas scans. This was done blind to 
the type 2 diabetes and normal glucose tolerance status. Two observers agreed the 
score for each pancreas in consensus.  
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At baseline, 44 type 2 diabetes subjects and 14 normal glucose tolerant control 
subjects had pancreas volume and triglyceride content measured after a 10 hours 
overnight fast. 
The type 2 diabetes subjects were randomised to receive either DPP-4 inhibitor or 
placebo in addition to metformin as described in CHAPTER 3. Measurements were 
also carried out at baseline, 1, 3 and 6 months of treatment, respectively Figure 4.1.  
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5.3 Results 
5.3.1 Pancreas volume 
Mean pancreas volume was smaller in the type 2 diabetes compared with the control 
group (55.5±2.8 vs. 82.6±4.8cm3; p<0.0001) Figure 5.1. Hence the pancreas was one 
third smaller in the type 2 diabetes subjects. In the type 2 diabetes group, pancreas 
volume ranged from 20.8 to 99.7cm3, and in the control group from 60.1 to 124.2cm3. 
Expression of the data as pancreas volume index did not change the extent of 
difference between the groups (33%; 27.8±1.3 vs. 41.7±2.5cm3/m2; p<0.0001). When 
the data were expressed as ratio of pancreas volume to waist ratio, there was a 38% 
decrease in the type 2 diabetes group (0.53±0.03 vs. 0.85±0.06; p<0.0001). 
 
 
 
Figure 5.1 Mean pancreas volume in the type 2 diabetes and control groups 
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5.3.2 Relationship of pancreas volume to insulin secretion 
There was a positive correlation between HOMA-B and pancreas volume in the type 2 
diabetes (r=0.31; p=0.03), control (r=0.46; p=0.05), and in the whole population studied 
(r=0.37; p=0.003) Figure 5.2. Pancreas volume was inversely proportional to age in 
those less than 60 years in the type 2 diabetes (n=7; r=-0.56; p=0.02), but this could 
not be demonstrated in the control group, probably as a type 2 statistical error (n=6; 
r=-0.66; p=0.09). Pancreas volume did not correlate with the duration of type 2 diabetes 
(r=-0.15; p=0.19). 
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Figure 5.2 Relationship between HOMA-B (%) and pancreas volume (cm3) in the type 
2 diabetes group (top), control group (middle) and combined group (bottom).  
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5.3.3 Effect of DDP-4 inhibition on pancreas volume 
Pancreas volume remained constant over 6 months in both the placebo plus metformin 
treated (60.5±2.0 to 60.6±4.5cm3) or the vildagliptin plus metformin treated type 2 
diabetes groups (50.4±4.1 to 51.8±4.2cm3; p=0.20).  
 
 
5.3.3.1 Pancreas morphology 
The pancreata of type 2 diabetes subjects were typically involuted, with a feathery, 
irregular border when compared with age, weight and sex matched glucose tolerant 
controls Figure 5.3. The semi-quantitative analysis of irregularity of the border of the 
pancreas is shown in Figure 5.4. Most type 2 diabetes subjects were deemed to have 
an irregular pancreatic outline (modal score 3). The distribution of scores was 
significantly different between type 2 diabetes and normal glucose tolerant subjects 
(p<0.002). 
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Figure 5.3 Comparison of the morphology of the pancreata of type 2 diabetes (left) and 
normal glucose tolerant subjects (right) demonstrating the more irregular anterior 
(uppermost) border of the pancreata. [TDM=type 2 diabetes subjects; NGT=normal 
glucose tolerant subjects]
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Figure 5.4 Semi-quantitative analysis of the irregularity of the pancreas outline.  Most 
irregular = 1 and least irregular = 5. It can be seen that the most non-diabetic 
individuals have a smooth pancreas outline whereas many people with type 2 diabetes 
have an irregular outline. The distribution of scores is significantly different (p<0.002) 
 
 
5.3.3.2  Intra-pancreatic triglyceride 
Pancreas triglyceride content was 23% higher in type 2 diabetes compared with normal 
glucose tolerant (5.4±0.3 vs. 4.4±0.4%; p=0.02) Figure 5.5. There was a positive 
correlation between pancreas triglyceride and BMI in normal glucose tolerant (r=0.64; 
p=0.008) but this was not present in type 2 diabetes (r= -0.10; p=0.29). There was a 
positive correlation between pancreas and liver triglyceride in the normal glucose 
tolerant (r=0.63; p=0.01) but this was lost in type 2 diabetes (r=0.02; p=0.46), and in 
the whole group (r=0.18; p=0.10).  
Pancreas triglyceride content remained unchanged at 6 months during placebo and 
metformin treatment of type 2 diabetes (5.6±0.4 vs. 5.5±0.5%; p=0.90), and there was 
also no difference between the vildagliptin and metformin treated group (5.1±0.4 to 
5.0±0.2%; p=0.74).  
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Figure 5.5 Pancreas triglyceride content in the type 2 diabetes and control group 
98 
 
5.4 Discussion 
This study demonstrates that pancreas volume is 33% smaller in individuals with type 
2 diabetes well controlled on metformin compared to normal glucose tolerant controls 
matched for age, weight and BMI. Insulin secretion assessed by HOMA-B was 
proportional to pancreas size in the type 2 diabetes, control and combined groups. A 
unique serrated boundary of the pancreas early in type 2 diabetes has been described 
for the first time. Not only is the pancreas small and involuted in appearance but also 
it has a 23% higher triglyceride content compared with that of well-matched glucose 
tolerant individuals.  
Several previous studies have assessed the size of the pancreas in type 2 diabetes. A 
retrospective study of individuals who had undergone abdominal CT scan reported a 
small decrease in pancreas volume in type 2 diabetes (7%; p<0.05). However, the 
group was unusual in having a low BMI (25.4kg/m2), and body weight was not matched 
between the type 2 diabetes and control groups (Saisho et al., 2007). Two ultrasound 
studies have examined pancreas volume in type 2 diabetes. One observed an 11% 
decrease in pancreas volume compared to the controls (Alzaid et al., 1993). However, 
the type 2 diabetes subjects studied had a longer duration of 9 years and fasting 
plasma glucose of 13mmol/l. The larger study of 84 type 2 diabetes and 80 controls 
subjects matched for age, sex and body mass observed a 22% decrease in area of the 
pancreas (Migdalis et al., 1991). However, the abnormality has not been widely 
recognized. The present study used a new method of defined precision to demonstrate 
a 33% decrease in pancreas volume in people with type 2 diabetes who are well 
controlled on metformin.  
Further analysis in the type 2 diabetes group demonstrated a significant difference in 
mean basal insulin concentration between those with pancreas volume <50cm3 (n=16) 
compared to those with pancreas volume >50cm3 (n=23); (7.9±2.2mU/L; p=0.0009), 
and this supports the association between pancreas volume and endocrine function. 
Although the endocrine pancreas consisting of the islet cells accounts for only 1% of 
total pancreas tissue, pancreas volume was found to be reduced by a third in this study. 
Therefore it is reasonable to speculate that the exocrine pancreatic tissue may also be 
reduced in type 2 diabetes. This is likely to be an effect of loss of the anabolic or trophic 
effects of insulin especially after each meal. Normally, plasma insulin concentrations 
rise markedly, and the rise in concentration of insulin within the interstitial tissue of the 
whole pancreas is likely to be much greater. The clear effect of loss of insulin secretory 
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capacity on the pancreas volume in type 1 diabetes supports this proposed mechanism 
(Foulis and Frier, 1984). 
The question of cause and effect is immediately posed by the demonstration of a small, 
involuted pancreas early in the natural history of type 2 diabetes. Are people with a 
small pancreas predisposed to develop type 2 diabetes, or is the decrease in pancreas 
volume a consequence of the ongoing pathological processes? It has been postulated 
that cell mass may be subnormal in those predisposed to develop type 2 diabetes 
(Bagust and Beale, 2003). However, in the absence of the means of measuring this in 
vivo, it has not been possible to examine this possibility. It is known that low birth weight 
is a risk factor for type 2 diabetes (Barker et al., 1993), and it may be considered that 
this could be associated with a smaller pancreas. If this is correct, it could be 
interpreted as indirectly supporting the possibility of low pancreas volume and hence 
low β cell mass as predisposing factors for type 2 diabetes.  
It has been suggested that approximately 20 genes may be associated with 
predisposition to type 2 diabetes (Prokopenko et al., 2008) and majority of these genes 
are thought to contribute to β cell dysfunction (Gloyn and McCarthy, 2008). Although 
the precise mechanism involved is unknown, TCF/L2 gene silencing has been strongly 
linked to an inhibitory effect on glucose-induced insulin secretion in type 2 diabetes 
(Grant et al., 2006).  
However, pancreas volume could secondarily be affected of the loss of normal post-
meal rise in insulin concentration by a paracrine effect. After meals, the local intra-
pancreatic rise in concentration must vastly exceed the 10 - 15 fold rise achieved in 
plasma concentration (Carey et al., 2005). Therefore, pancreatic tissue is likely to be 
exposed to very high concentrations of insulin under normal circumstances. When 
there is no local insulin production as in type 1 diabetes, pancreas volume is known to 
be decreased by one third (Foulis and Frier, 1984) and this is evident within months of 
diagnosis (Williams et al., 2012).  As such it is reasonable to postulate that phasic 
secretion of insulin, with concentration at least 10 fold greater than required for 
metabolic effects (Poggi et al., 1979) achieved with meals promotes growth locally by 
binding to IGF1 receptors. In type 2 diabetes basal insulin levels are raised but there 
is an absence of immediate and major insulin release after meals, which could explain 
a lack of growth promoting concentrations of the hormone. It is reasonable to postulate 
that normalisation of phasic insulin secretion in type 2 diabetes with calorie restriction 
may restore pancreas volume and outline. The recovery of β cell function after calorie 
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restriction is likely to depend upon release from the inhibitory effects of lipid 
metabolites. This relatively rapid process contrasts with longer time course likely to be 
required to change volume of the whole pancreas. Clinical studies will be required to 
examine the effect of calorie restriction on pancreas morphology. Studies in non-
human primates have observed an approximate 10% decrease in pancreas volume 2 
- 6 months after low dose streptozotocin, but at each time point only single animals 
were observed and statistical significance could not be demonstrated (Saisho et al., 
2011). 
This work establishes a significant relationship between pancreas volume and HOMA-
B in both type 2 diabetes and control groups, but the latter is an estimate of overall β 
cell insulin responsiveness and not a measure of glucose-mediated acute insulin 
secretion. Further work is required to define the precise relationship of first phase 
insulin response to pancreas volume.   
The association of pancreas triglyceride with type 2 diabetes remains contentious. A 
cross-sectional study using ultrasound of 7,464 individuals showed higher pancreas 
triglyceride levels to be associated with both type 2 diabetes and pre-diabetes (Bi et 
al., 2013). Magnetic resonance spectroscopy allows measurement of intra-organ 
triglyceride, although, this relies upon correction for respiratory movement in defining 
tissue which is definitely within the pancreas.  Using this method, it has been shown 
that higher pancreas triglyceride levels are associated with raised basal insulin levels, 
and that this relationship is present in different ethnic groups (Szczepaniak et al., 
2012). The wide scatter of absolute levels of pancreas triglyceride with a tendency for 
higher levels in people with diabetes has been confirmed (Tushuizen et al., 2007). The 
latter study showed that pancreas triglyceride correlated negatively with early glucose-
stimulated insulin secretion.  
Great care is required using the spectroscopic method as the fat signal could be 
contaminated by the stronger signal from surrounding visceral adipose tissue, and 
because of this an imaging-based method was developed (Lim et al., 2011a). All 
analysis is conducted on an acquired image by this method and not on a pre-
determined volume of the body, the contents of which may change with respiration or 
movement. This method permits higher precision of measurement (Lim et al., 2011a). 
The present results apply the 3-point Dixon method of magnetic resonance imaging to 
well characterized individuals with type 2 diabetes subjects well controlled on 
metformin only and demonstrate that pancreas triglyceride content is 23% higher than 
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in age, weight and sex matched normal controls. Additionally, the data indicate that the 
normal positive correlation between pancreas and liver fat is lost in type 2 diabetes 
subjects. 
The mechanism through which long-term lipid exposure to the pancreas impairs 
glucose stimulated insulin secretion has been examined. Although it has been 
suggested that the suppression of mitochondrial pyruvate cycling may play a role in 
the loss of glucose stimulated insulin secretion (Boucher et al., 2004), a longitudinal 
study of aetiopathogenesis of type 2 diabetes using the new method has confirmed 
that weight-loss induced decrease in pancreatic triglyceride is temporally associated 
with restoration of normal glucose stimulated acute insulin secretion (Lim et al., 2011a).   
The limitations of the present observation must be considered. Firstly, although 
measurement of organ volume is routine in radiographic practice, it has not previously 
been applied to the study of the pancreas in diabetes. The accuracy and precision of 
the method applied to pancreas require to be examined. Accuracy of such 
methodology is rarely established, but one study has shown volumetry by magnetic 
resonance imaging to correspond almost exactly to water displacement for pancreata 
of mini-pigs (Szczepaniak et al., 2013). Good intra- and inter-observer agreement as 
reflected in the Bland-Altman plots were demonstrated. Additionally, repeat 
measurements after 6 months of vildagliptin or placebo treatment were highly 
consistent. Thus the measurement of pancreas volume by magnetic resonance 
imaging with BTFE can be regarded as robust. Secondly, assessment of irregularity of 
shape of the pancreas can only be regarded, as semi-quantitative and further work is 
required to develop a mathematical method for measuring deviation from a smooth but 
variable curve. Thirdly, accuracy and precision of pancreas triglyceride must be 
considered. Data on accuracy of human pancreas triglyceride measurement is lacking, 
due to the rapid enzyme mediated autolysis of the pancreas post-mortem. However, 
the Newcastle MR group has previously reported an excellent inter-scan Bland-Altman 
coefficient (Lim et al., 2011a), and the 3-point Dixon method used gives almost 
identical absolute measurements of intra-pancreatic triglyceride compared to that 
obtained by the centre with the largest experience of measurement using magnetic 
resonance spectroscopy (Szczepaniak et al., 2013).  Finally, the type 2 diabetes group 
was large for this type of detailed study. Although the group of subjects with proven 
normal glucose tolerance was smaller, the consistency of measured outcomes within 
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the relatively homogenous control group allowed confident identification of the major 
abnormalities associated with type 2 diabetes.  
In summary, this study has demonstrated that in a group of type 2 diabetes individuals 
with good metabolic control on metformin the pancreas is 33% smaller, typically 
involuted and has raised triglyceride content compared to normal. These gross 
abnormalities could potentially yield prognostic information. Further work must 
elucidate their relationships with the pre-diabetes phase, their interaction with 
treatment modalities and changes during the natural history of type 2 diabetes.  
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CHAPTER 6 Direct assessment of diurnal glycogen storage 
6.1 Introduction 
In normal health, the control of postprandial plasma glucose depends upon timely 
storage of meal-derived glucose as glycogen in the liver and skeletal muscle. In young 
healthy humans, approximately 30% of carbohydrate absorbed is stored as skeletal 
muscle glycogen in the immediate postprandial period (Taylor et al., 1993) and 
approximately 20% as liver glycogen (Taylor et al., 1996). If no food is taken over the 
next 7 hours, glycogen concentration in both muscle and liver decline. Glucose carbon 
is glycolysed to lactate and exported to fuel hepatic gluconeogenesis in order to 
maintain glucose supply largely for brain and red blood cell oxidative needs. However, 
when meals are taken at intervals of 4 - 5 hours during the day, there is a sequential 
rise in muscle and liver glycogen concentration in healthy volunteers (Hwang et al., 
1995; Carey et al., 2003). Tissue glycogen concentrations would be expected to be 
maximal after the evening meal prior to the overnight fall to fasting levels.  
These data suggest that muscle and liver act to buffer the plasma changes in glucose 
concentration after meals by storing the osmotically active metabolite in an inert form, 
hence preventing large postprandial swings in plasma glucose concentration. In type 
2 diabetes, inadequate glucose storage as glycogen has been previously reported, and 
the postprandial rise in plasma glucose concentration is excessive (Mitrakou et al., 
1990; Carey et al., 2003; Krssak et al., 2004). However, the extent of abnormality has 
not been defined for the buffering function of glycogen storage in muscle and liver 
during day-long eating in type 2 diabetes. Additionally, data on the effect of therapeutic 
DPP-4 inhibition on tissue glycogen storage in type 2 diabetes is lacking. The purpose 
of this study was to quantify the maximum daily flux of muscle and liver glycogen in 
people with well controlled type 2 diabetes compared to matched glucose tolerant 
controls, and to characterise the effect of vildagliptin on day-long eating.  
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6.1 Study design 
6.1.1 Subjects 
The clinical and metabolic description of 44 type 2 diabetes and 14 normal glucose 
tolerant subjects matched for age, weight and BMI subjects are given in CHAPTER 3. 
The characteristics for both groups is summarised in Table 5.1. The study was 
approved by the Newcastle and North Tyneside 2 Research Ethics Committee. 
 
 
6.1.2 Study protocol 
Fasting and post-evening meal muscle and liver glycogen concentrations were 
measured by 13C MR spectroscopy as described in CHAPTER 2. All subjects were 
asked to avoid vigorous exercise and take no alcohol for 3 days prior to assessment. 
At baseline, all subjects attended for measurements of fasting and post-evening meal 
muscle and liver glycogen concentration, plasma glucose, insulin, glucagon and 
triglyceride concentration. The measurements were repeated at 6 months. 
The type 2 diabetes subjects were randomised (ratio 1:1) in a double-blinded fashion 
to receive either vildagliptin 50mg bid or placebo. All committed to take metformin 
therapy at a stable dose. Further measurements of fasting muscle and liver glycogen 
concentration in the type 2 diabetes subjects (vildagliptin and placebo groups) were 
carried out at 1 and 3 months Figure 4.1. 
On the morning of first day after a 10 hour overnight fast, subjects were transported to 
the study centre by taxi and measurements commenced at 0800h. Blood samples for 
plasma glucose, insulin, glucagon and triglyceride concentration were taken; then 
magnetic resonance (MR) measurements of fasting muscle and liver glycogen 
concentration were performed. Only water was allowed during the fasting period, and 
all subjects with type 2 diabetes were advised to omit their morning dose of metformin. 
Postprandial measurements after a day of three standard meals were carried out at 
least 3 days after fasting assessments. All food for the study day had been previously 
provided and subjects were asked to consume all of the meals but nothing in addition 
to that provided. Meal composition is detailed in Appendix 2. Meals were eaten at 
0800h, 1200h, at 1600h. The type 2 diabetes subjects took their usual doses of 
metformin tablets 5 minutes before meals. Blood samples were taken at 2000h, and 
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then MR measurements were performed immediately Figure 6.1. This ensured that 
muscle and liver post-meal glycogen concentrations were measured 4 hours after the 
third meal, when maximal net glycogen storage from the three meals would be 
expected.  
 
 
 
Figure 6.1 Post meal skeletal muscle and liver glycogen concentration measured by 
MR spectroscopy 
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6.2 Results 
6.2.1 Muscle glycogen concentration 
At baseline, mean fasting muscle glycogen concentration did not differ between the 
type 2 diabetes and normal glucose tolerant groups (68.3±2.6 vs. 68.1±4.8mmol/l; 
p=0.82). At 4 hours after the third meal, muscle glycogen concentration rose by 17.3% 
in the normal glucose tolerant group (68.1±4.8 to 79.7± 4.2mmol/l; p=0.0006) Figure 
6.2. In the type 2 diabetes group, muscle glycogen concentration remained unchanged 
over the same time period (68.3 ± 2.6 to 67.1 ± 2.0mmol/l; p=0.62). The change in 
diurnal muscle glycogen concentration inversely correlated with HOMA-IR only in the 
normal glucose tolerant group (r = -0.56; p=0.02) Figure 6.3.  
 
 
 
Figure 6.2 Diurnal change in muscle glycogen concentration. Fasting and post-three 
meal concentrations are shown for the normoglycaemic control and type 2 diabetes 
groups
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Figure 6.3 Correlation between HOMA-IR and change in muscle glycogen 
concentration in the normoglycaemic control subjects 
 
Fasting muscle glycogen concentration was similar between the vildagliptin treated 
and placebo groups at baseline (70.5±4.3 vs. 65.9±23.0mmol/l; p=0.82). In the 
vildagliptin treated group, fasting muscle glycogen concentration remained unchanged 
at 1 month (68.6±3.6 vs. 64.8±3.3mmol/l p=0.43), at 3 months (66.4±2.9 vs. 66.0± vs. 
3.2mmol/l), and at 6 months (67.5±2.4 vs. 64.4±3.0mmol/l; p=0.43). After 6 months of 
vildagliptin treatment, muscle glycogen concentration 4 hours after the third meal 
remain unchanged (69.0±2.5 to 66.0± 3.3mmol/l; p>0.05). 
 
 
6.2.2 Liver glycogen concentration 
At baseline, fasting liver glycogen concentration was similar in the type 2 diabetes and 
normal glucose tolerant groups (296.1±16.0 vs. 325.9±25.0mmol/l; p=0.24). At 4 hours 
after the third meal, liver glycogen concentration was higher in both groups (296.1±16.0 
to 350.5±6.7mmol/l; p<0.0001 and 325.9±25.0 to 388.1±30.3mmol/l; p=0.005), 
respectively; and there was no significant difference between the groups (p=0.31). The 
per cent diurnal glycogen change was comparable between the type 2 diabetes and 
normal glucose tolerant groups (18 vs. 19%) Figure 6.4.
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Figure 6.4 Diurnal change in liver glycogen concentration. Fasting and post-three meal 
concentrations are shown for the normoglycaemic control and type 2 diabetes groups 
 
Fasting liver glycogen concentration was similar between the vildagliptin treated and 
placebo groups at baseline (303.3±22.47 vs. 288±23.4mmol/l). In the vildagliptin 
treated group, fasting liver glycogen concentration remained unchanged at 1 month 
(303.2±21.1 vs. 299.9±17.4mmol/l), at 3 months (296.9±19.3 vs. 302.1± 
vs.21.9mmol/l), and at 6 months (308.5±27.5 vs. 298.2±19.8mmol/l). After 6 months of 
vildagliptin treatment, liver glycogen concentration 4 hours after the third meal was 
similar in both vildagliptin treated (313.7±26.3 to 349.4±25.9mmol/l) and placebo group 
(280.1±18.2 to 354.0±24.3mmol/l). 
 
 
6.2.2.1 Plasma glucose, metabolites and hormone concentration 
6.2.2.2 Plasma glucose concentration 
Baseline plasma glucose concentration was higher in the type 2 diabetes group than 
the normal glucose tolerant group, at both fasting (7.7±0.2 vs. 5.1±0.1mmol/l; 
p<0.0001) and 4 hours after the third meal (6.5±0.2 vs. 5.7±0.2mmol/l; p=0.03). There 
was no difference in baseline fasting plasma glucose concentration between the 
vildagliptin treated and placebo groups (7.7±0.2mmol/l vs.7.8±0.3mmol/l).  
At the 6 months time point, blood glucose concentration at 4 hours after the third meal 
was not significantly different between the vildagliptin treated and placebo group 
(6.3±0.3 vs.6.8±0.3mmol/l; p=0.22) Figure 6.5a. However, in the placebo group a 
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significant rise had occurred (p<0.02), whereas in the vildagliptin group a significant 
fall (p=0.05) was observed. 
 
 
6.2.2.3  Plasma insulin concentration  
Baseline plasma insulin concentration was higher in the type 2 diabetes group than the 
normal glucose tolerant group at both fasting (13.8±1.2 vs. 7.9±0.9mU/L; p=0.01) and 
4 hours after the third meal (31.9±2.9 vs. 18.8±3.3mU/L; p=0.03). Plasma insulin 4 
hours after the third meal was higher than fasting in the normal glucose tolerant group 
(7.9±0.9 to 18.8±3.3mU/L; p=0.003). Similarly in the type 2 diabetes group, plasma 
insulin rose from 13.8±1.2 to 31.9±2.9mU/L (p<0.0001).  
Plasma insulin concentration at baseline was comparable between the vildagliptin 
treated and placebo groups, both at fasting (13.0±1.8 vs. 14.8±1.6mU/L; p=0.33) and 
at 4 hours after the third meal (30.8±3.0 vs. 33.8±4.9mU/L; p=0.61).  
At the 6 months time point, plasma insulin concentration after the third meal was 
significantly lower in the vildagliptin treated group (22.3±2.7 vs. 32.3±3.8mU/L; 
p=0.001) Figure 6.5b.  
 
 
6.2.2.4 Plasma glucagon concentration 
Baseline plasma glucagon concentration was higher in the type 2 diabetes group than 
the normal glucose tolerant group at both fasting (70.4±4.7 vs. 48.4±4.8ng/L; p=0.01) 
and 4 hours after the third meal (108.5±7.5 vs. 67.7±7.3ng/L; p<0.001).  
Plasma glucagon concentration at baseline was not statistically different in the 
vildagliptin treated and placebo group at both fasting (64.1±5.8 vs. 73.7±7.1ng/L; 
p=0.31) and 4 hours post meal (107.8±10.2 vs. 110.2±12.0ng/L; p=0.88), respectively. 
At the 6 months time point, plasma glucagon concentration was significantly lower in 
the vildagliptin treated group after the third meal (82.6±7.9 vs. 106.1±12.7ng/L; p=0.01) 
and also at fasting (47.7±6.2 vs. 60.1±5.8ng/L; p<0.0001) Figure 6.5c.
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6.2.2.5 Plasma triglyceride concentration 
At baseline, plasma fasting triglyceride concentration was comparable in the type 2 
diabetes and normal glucose tolerance groups (1.4±0.1 vs. 1.5±0.3mmol/l; p=0.90). At 
4 hours after the evening meal, triglyceride levels rose in both type 2 diabetes (1.4±0.1 
to 2.2±0.1mmol/l; p<0.0001) and in the normal glucose tolerant group (1.5±0.3 to 
2.3±0.3mmol/l; p=0.007), respectively.  
Baseline plasma fasting triglyceride concentration was similar in the vildagliptin treated 
and placebo groups (1.5±0.1 vs. 1.5±0.1mmol/l). The change from fasting to post 
evening meal plasma triglyceride concentration was similar in both the vildagliptin and 
placebo groups at baseline (1.5±0.1 to 2.2±0.2mmol/l; p<0.001). 
At the 6 months time point, plasma triglyceride concentration 4 hours after the third 
meal was significantly lower in the vildagliptin treated (2.2±0.2 vs. 1.9±0.1mmol/l; 
p=0.045)  Figure 6.5d. 
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Figure 6.5 Postprandial changes in (a) glucose, (b) insulin, (c) glucagon and (d) 
triglyceride concentration for the control and vildagliptin treated groups at baseline and 
at 6 months. The dotted blue line indicates the postprandial concentration for the 
normal glucose tolerant subjects
(a) 
 
 
 
 
 
 
(b) 
 
 
 
 
 
 
(c) 
 
 
 
 
 
 
(d) 
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6.3 Discussion 
This study has defined the extent of daylong glycogen storage in muscle and liver 
during normal eating in both people with well controlled type 2 diabetes and with normal 
glucose tolerance. The data show that under normal everyday eating, skeletal muscle 
does not contribute to glycogen storage in people with early, well controlled type 2 
diabetes. In contrast, daylong storage of glycogen in liver was similar between the type 
2 diabetes and normal glucose tolerant groups. In normal glucose tolerant individuals 
muscle and liver were shown to act together as dynamic buffers, storing osmotically 
active glucose temporarily and allowing redistribution of carbon energy overnight.  
Previous studies with either euglycaemic hyperinsulinaemic (Basu et al., 2001) or oral 
glucose administration (Firth et al., 1986; Kelley and Mandarino, 1990; Mitrakou et al., 
1990; Kelley and Simoneau, 1994) have shown that the rate of muscle glucose uptake 
is subnormal in subjects with type 2 diabetes, and this is reflected by higher blood 
glucose concentration in diabetic subjects. The present data demonstrate that under 
everyday conditions postprandial storage of glucose as glycogen in muscle is markedly 
impaired in type 2 diabetes. This sets into a physiological context the demonstration of 
direct observation of subnormal insulin stimulated rate of glycogen synthesis in type 2 
diabetes subjects using labelled 13C-glucose (Shulman et al., 1990b).  
Natural abundance 13C MR spectroscopy has previously been applied to measure 
change in muscle and liver glycogen concentration in type 2 diabetes (Carey et al., 
2005). In a group of people with type 2 diabetes who had similar BMI but less tight 
blood glucose control than the present experimental group, muscle glycogen 
concentration did not rise significantly after two successive meals although there 
appeared to be a modest upward trend. The present data demonstrate that there is no 
net contribution of muscle glycogen to meal derived glucose storage during a full day 
of eating. The complete lack of increase in muscle glycogen following three meals is 
all the more striking when the ambient plasma insulin levels are considered. Both 
fasting and 4 hours after the third meal, plasma insulin levels were over 50% higher in 
type 2 diabetes, illustrating the practical everyday extent of muscle insulin resistance 
of type 2 diabetes.  
The likely aetiology for the lack of glycogen storage in the skeletal muscle must be 
considered. The translocation of GLUT 4 membrane transporters has been shown to 
be impaired in individuals with insulin resistance (Garvey et al., 1998). In skeletal 
muscle, glucose uptake via the GLUT 4 membrane transporters is the rate-limiting step 
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for glycogen storage (Yki-Jarvinen, 1990; Roden et al., 1996; Cline et al., 1999). 
Resistance to insulin stimulated glucose uptake by muscle has been shown to precede 
the onset of type 2 diabetes by decades (Lillioja et al., 1988; Warram et al., 1990). The 
defect specifically involves muscle glycogen synthesis as shown by clamp studies 
using 13-C labelled glucose infusion and MR spectroscopy (Shulman et al., 1990a). 
As exercise training and weight loss both have the potential to ameliorate this defect, 
these interventions have been intensively studied.  Although 6 weeks of intensive 
aerobic exercise increased insulin dependent muscle glucose uptake, this did not 
change relative to the non-diabetic control group (Perseghin et al., 1996). Weight loss 
sufficient to restore durable normoglycaemia had no effect upon insulin sensitivity 
measured by insulin clamp (Lim et al., 2011a). The defect in muscle glycogen synthesis 
appears to be a central aspect of the aetiopathogenesis of type 2 diabetes (Taylor, 
2013).  
The normality of the capacity of the liver to store glycogen in type 2 diabetes is striking 
in contrast to the absence of insulin stimulation of glycogen synthesis in muscle. This 
is likely to represent the very different glucose handling in this tissue compared with 
muscle. Unlike in skeletal muscle where glucose uptake via GLUT 4 glucose 
transporters is the rate-limiting step for glycogen storage, there is no insulin regulation 
of cellular glucose uptake by the hepatocyte. Liver glucose concentration inside the 
hepatocyte reflects that of the extracellular fluid, and hepatic glycogen synthesis is 
responsive to glucose concentration such that hyperglycaemia increases the rate of 
this process by mass action (Agius et al., 1990). This will be reflected in the overall 
rate of storage in type 2 diabetes being expedited by the ambient hyperglycaemia 
following each meal, in addition to the effect brought about by insulin. Hence the normal 
diurnal increment in hepatic glycogen concentration cannot be interpreted as indicating 
normal insulin sensitivity of this metabolic pathway. When plasma glucose is clamped, 
hepatic glycogen synthesis rate has been shown to be subnormal (Krssak et al., 2004). 
The same paper reported decreased rates of hepatic glycogen storage following a test 
meal in type 2 diabetes, and the reasons for the lack of accord with the present data 
must be considered. This is most likely to relate to the different groups studied. In the 
previously reported study (Krssak et al., 2004), the type 2 diabetic subjects (n=7) were 
close to normal weight (BMI 26.9kg/m2) with HbA1c of 7.1%; whereas in the present 
study the type 2 diabetic group (n=41) had a more typical mean BMI of 30kg/m2 and 
were at an earlier stage of the condition with HbA1c of 6.4%. The latter point is important 
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to illustrate that type 2 diabetes develops whilst post-prandial hepatic glycogen 
metabolism is normal.  
Knowledge of the physiological mechanisms involved in substrate storage and 
maintenance of glucose homeostasis is central to the appreciation of normal energy 
metabolism in humans (Mitrakou et al., 1990). The present data quantify the ranges 
between which glycogen concentration in muscle and liver vary during diurnal 
substrate ingestion. The nocturnal usage of glycogen stores requires to be considered. 
In liver, the stored glucose will directly contribute to the ongoing hepatic glucose 
production overnight by glycogenolysis. In muscle, the carbon energy cannot be 
exported as glucose, due to the lack of glucose-6-phosphatase, and is instead 
exported as lactate or pyruvate. The process of peripheral export of these 3-carbon 
fragments and utilization for gluconeogenesis is described as Cori cycle activity (Dunn 
et al., 1967). Although classically this is regarded as a futile cycle, moving glucose 
carbon to peripheral tissues and recycling this to liver, it can be seen that the temporal 
shift in storage and export allows a vital function to prevent postprandial 
hyperglycaemia to be satisfied. Hence, in normal health, glycogen stores in muscle 
and liver are built up during daytime eating and underpin the essential overnight 
maintenance of plasma glucose, to support brain glucose oxidation.  
In the normal glucose tolerant control group there was a correlation between 
intramyocellular lipid and insulin sensitivity as quantified by HOMA-IR; higher 
intramyocellular lipid tended to be associated with lower postprandial increase in 
muscle glycogen as previously reported (Krssak et al., 1999). In the type 2 diabetes 
subjects intramyocellular lipid was raised and there was no net increase in muscle 
glycogen. As a consequence there was no correlation between lipid stores and extent 
of diurnal glycogen cycling in muscle. In the liver, there was no relationship between 
lipid stores and extent of postprandial storage of glycogen in either group, most likely 
reflecting the lack of a lipotoxic effect upon control of cellular glucose uptake in the 
liver. This contrasts with the close relationship between intrahepatic lipid and insulin 
sensitivity of hepatic glucose production (Seppala-Lindroos et al., 2002; Petersen et 
al., 2005; Lim et al., 2011a). Additionally, when the mass action effect of glucose on 
hepatic uptake is removed a significant inverse relationship can be demonstrated 
during hyperglycaemic hyperinsulinaemic clamp in type 2 diabetes and control 
subjects. The difference between this experimental fixed condition, designed to give 
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insight into mechanisms, and the everyday condition investigated in the present study 
is important to appreciate.  
This study did not show any change in glucose storage in the muscle and liver with 
vildagliptin. It can be postulated that DPP-4 inhibition has no effect on the translocation 
of GLUT 4 transporters and this accounts for the lack of increase in muscle glycogen 
storage after 6 months treatment with vildagliptin. Although a small decrease in 
intramyocellular lipid was observed (22.5±2.9 to 18.5±2.3mmol/l) in the vildagliptin 
treated group, this was not statistically significant and did not influence muscle insulin 
sensitivity or glucose storage. The relatively small number of subjects analysed lacked 
sufficient power to allow definite conclusions to be made. Therefore a potential effect 
on muscle glycogen storage could not be seen. Intramyocellular lipid is technically 
difficult to measure in obese people and as such we were only able to obtain 
measurements for 14 vildagliptin treated and 12 placebo subjects.  
The extent of diurnal liver glycogen storage was comparable between the type 2 
diabetes and normal glucose tolerance group at baseline and at 6 months. Although 
vildagliptin has been shown to decrease hepatic triglyceride content, a marker of  
hepatic insulin sensitivity, hepatic glycogen storage is mostly dependent on 
extracellular glucose concentration (Agius et al., 1990).  
The study showed that vildagliptin lowers postprandial insulin, glucagon and TG 
concentrations in subjects with type 2 diabetes, and this is consistent with previous 
studies (Matikainen et al., 2006; Vella et al., 2007; Ahren et al., 2010). Consequently 
insulin and glucagon are appropriately secreted to reflect normal physiology. The 
results suggest vildagliptin may restore normal postprandial insulin and glucagon 
profile in subjects with the type 2 diabetes. Such a profile would be characterised by 
earlier control of post - prandial glucose and lower the need for insulin in the late post 
- prandial phase.  It has been suggested that the lower levels of insulin and glucagon 
are as a result of vildagliptin-mediated increase in α and β cell sensitivity to glucose 
concentration (Ahren et al., 2010). Whereas metformin alone is thought to bring about 
a direct suppression on hepatic glucose production, DDP-4 inhibition has a clear effect 
through glucagon suppression (Solis-Herrera et al., 2013). The combined effects of 
DDP-4 inhibitor and metformin may contribute to a clinical improvement in postprandial 
glucose concentration and overall glycaemic control.  
The effect of vildagliptin on postprandial glucose excursion warrants careful 
consideration. If vildagliptin is taken immediately before an evening meal, postprandial 
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glucose excursion and inappropriate glucagon secretion are reduced, and these 
effects continue beyond the postprandial period (Balas et al., 2007). As such 
postprandial hepatic glucose production is reduced and fasting plasma glucose falls.  
This study has quantified the extent of day-long storage of food-derived glucose as 
muscle and liver glycogen in type 2 diabetic and matched normoglycaemic individuals. 
Muscle glycogen storage was completely inactive in type 2 diabetes whereas liver 
glycogen storage was normal. The data define the extent of post-prandial glucose 
storage as glycogen in health and identify an important contributor to post-prandial 
hyperglycaemia.  
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CHAPTER 7 General Discussion 
7.1  Overview 
The work reported in this thesis advances basic knowledge about type 2 diabetes and 
also demonstrates a previously unrecognised mechanism of action of a DPP-4 inhibitor 
drug. It was demonstrated that muscle glycogen storage was completely inactive in 
type 2 diabetes whereas liver glycogen storage was normal after a whole day of usual 
eating. The practical result of insulin resistance in muscle has not previously been 
made so evident and appeared to contribute significantly to the aetiopathophysiology 
of type 2 diabetes.  
A central feature of type 2 diabetes concerns the abnormality of β cell function, 
although the whole pancreas has not been extensively studied previously. This work 
showed that the volume of the pancreas in type 2 diabetes was 33% smaller than that 
of age, weight and BMI matched glucose tolerant controls. Furthermore, the pancreas 
in type 2 diabetes subjects was found to be involuted with pancreatic triglyceride 
content 23% higher than that of matched controls. 
It was demonstrated that vildagliptin (DPP-4 inhibition) therapy reduces hepatic 
triglyceride content by 27% in subjects with well controlled type 2 diabetes. The 
reduction in hepatic triglyceride remained significant even after applying correction of 
weight change, a major influence in hepatic triglyceride. The 27% fall in hepatic 
triglyceride was that observed when the data was analysed as described for a 
pharmaceutical trial; wherein a measured data at 3 months was carried forward if a 
subject had been in the study for at least 3 months but dropped out before 6 months. 
If non-completers were excluded, a 42% fall in hepatic triglyceride was observed; 
however this was not primary data. Postprandial plasma glucose, insulin, glucagon and 
triglyceride concentration also fell with 6 months of vildagliptin therapy. 
118 
 
7.2 Critique of methodology 
The conclusions depend very much upon the robustness and appropriateness of the 
methodology used. Firstly, well-controlled type 2 diabetes subjects were studied 
(HbA1c ≤ 7.6% or 60mmol/mol) on metformin only, with a mean duration of 5.9±0.8 
years and normal glucose tolerant subjects matched for age, weight and BMI. The 
subjects studied allowed vital conclusions to be drawn in early type 2 diabetes wherein 
lipotoxicity is a fundamental contributing factor to the aetiopathophysiology. MR 
techniques such as the three point Dixon (to measure liver and pancreas triglyceride 
concentration), 13C spectroscopy (to measure muscle and liver glycogen 
concentration), 1H spectroscopy (to measure IMCL concentration) are safe and have 
been shown to be robust. The techniques that have been described were used to 
measure intra-organ lipid concentration in the liver and muscle as a surrogate marker 
of insulin resistance. Diacylglyceride and ceramide have been directly implicated in 
abnormal insulin signalling, but it is presently impossible to measure their intra-organ 
concentration with MR techniques. It is hoped that further advancement in MR physics 
may permit direct in vivo measurement of metabolically active lipids. The measurement 
of IMCL concentration with 1H spectroscopy poses practical difficulties in our type 2 
diabetes group. Due to an increase in the surface to coil distance in our study 
population, it was difficult to obtain good quality spectra for analysis. As such, data was 
obtained in only 50% of the vildagliptin and placebo treated group, respectively, and 
therefore lacked sufficient power to detect any true difference. The euglycaemic 
hyperinsulinaemic clamp regarded as the gold standard method to assess insulin 
sensitivity was used to assess the effect of DPP-4 inhibitor in the defined study group. 
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7.3 Diurnal change in muscle and liver glycogen storage in type 2 diabetes 
The process of storing meal-derived glucose as glycogen in the muscle and liver is 
vital to maintaining normal postprandial glucose concentration in healthy humans as 
such massive swings in plasma glucose concentration after meals are prevented. If 
tissue uptake did not occur, a meal containing 80g of carbohydrate can be calculated 
to bring about a rise in plasma glucose of 32mmol/l for a 70kg person. Previous studies 
have demonstrated that approximately 30% of carbohydrate absorbed is stored as 
skeletal muscle glycogen in the immediate postprandial period (Taylor et al., 1993) and 
approximately 20% as liver glycogen (Taylor et al., 1996) in young healthy humans. 
Therefore the muscle and liver can be considered to act together as dynamic buffers, 
storing osmotically active glucose temporarily and allowing redistribution of carbon 
energy overnight. Although liver glycogen storage is mainly dependent on plasma 
glucose concentration, saturation kinetics will only allow approximately 20% of meal 
carbohydrate to be stored as liver glycogen. Half of meal carbohydrate will be utilised 
to maintain normal cell function. The outstanding 30% of meal carbohydrate, which is 
not utilised in liver glycogen storage or energy production, contributes to postprandial 
hyperglycaemia. Consequently, basal insulin secretion increases and this in turn drives 
de novo hepatic lipogenesis and sets into motion the Twin Cycle Hypothesis in type 2 
diabetes previously described Figure 7.1 (Taylor, 2013). 
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Figure 7.1 Adaptation of the twin cycle hypothesis of the aetiopathophysiology of type 
2 diabetes (Taylor, 2013)  
 
 
The lack of relationship between IMCL content and inability to store glycogen in the 
muscle in the type 2 diabetes group illustrates the role of muscle insulin resistance 
which precedes the onset of type 2 diabetes. Although muscle insulin resistance alone 
does not cause type 2 diabetes, it contributes to the pathogenesis of type 2 diabetes 
by causing a relative hyperinsulinaemic state which ultimately leads to hepatic 
triglyceride accumulation by stimulating hepatic de novo lipogenesis (Petersen et al., 
2007; Taylor, 2013). 
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7.4 Morphology and composition of the pancreas in type 2 diabetes  
An important observation on pancreas morphology was made. The pancreas in type 2 
diabetes subjects was observed to be small and involuted with a serrated boundary. It 
is remarkable that these combined abnormalities have not been previously detected 
and described.  
Several important questions arise. Does having a small pancreas, potentially with 
proportionally decreased numbers of β cells, predispose to developing type 2 
diabetes? Furthermore, could this be a consequence of inadequate intra-uterine 
development of the pancreas and hence explain the link with low birth weight (Barker 
et al., 1993)? Alternatively, could it be that the pancreas involutes as post-prandial 
insulin spikes are diminished by a paracrine effect? Some animal studies have shown 
that the inhibition of insulin secretion by low dose streptozotocin resulted in a modest 
decrease in pancreas volume (Saisho et al., 2011). After meals, the pancreas is 
exposed to insulin concentration far greater than the 10 - 15 fold increase observed in 
peripheral circulation (Carey et al., 2005). Meal stimulated supra physiological insulin 
concentration may bring about a growth promoting effect of the pancreas. In type 1 
diabetes, insulin secretion is negligible and pancreas volume is known to be decreased 
by one third (Foulis and Frier, 1984), and this change happens within months of 
diagnosis (Williams et al., 2012). Although basal insulin concentration is raised in type 
2 diabetes, there is complete lack of the acute first phase insulin secretory response 
after a meal. As such, peak intra-pancreatic supra physiological concentration of 
insulin required for a paracrine growth effect is not achieved.  
The higher triglyceride content of the pancreas, compared with that of well-matched 
normal glucose tolerant individuals that was observed, is consistent with previous 
studies with either ultrasound (Bi et al., 2013) or magnetic resonance spectroscopy 
(Szczepaniak et al., 2012). As human islets cells dramatically increase triglyceride 
stores when incubation with excess fatty acids in vitro (Diakogiannaki et al., 2007) and 
as islets cells exposed to excess fatty acids in vitro have been shown to decrease 
insulin secretion in response to an acute glucose stimulus (Lee et al., 1994b; 
Tushuizen et al., 2007), it is reasonable to postulate that the observed increased 
triglyceride content of the pancreas over time could be a direct cause of the loss of 
acute insulin secretory ability. The loss of acute insulin secretion due to intra-
pancreatic lipid accumulation could account for a lack of a paracrine growth effect of 
the pancreas. 
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7.5 Effect of vildagliptin on the liver 
Observation of improved post-prandial triglyceride handling during vildagliptin 
treatment suggested that other mechanisms other than an inhibitory effect on GLP-1 
breakdown might be operating. As accumulation of hepatic lipid is such a characteristic 
feature of type 2 diabetes (Taylor, 2013), the question of whether vildagliptin affected 
this central aspect of triglyceride metabolism needed to be answered. The data 
revealed a clinically useful decrease in liver triglyceride concentration over 6 months 
of vildagliptin therapy. As the fall in liver triglyceride was associated with a fall in plasma 
ALT, a marker of metabolic stress in the hepatocytes, it appeared that hepatocyte 
function improved simultaneously. The correlation between improvement in liver 
triglyceride and in plasma glucose concentration suggests a direct mechanistic link. 
Fasting plasma glucose fell by 0.9mmol/l and HbA1c normalised to the non-diabetic 
range. Additionally, the falls in liver triglyceride content and fasting plasma glucose 
positively correlated at 3 months (r=0.47; p=0.02) and 6 months (r=0.44; p=0.03). This 
effect can be attributable to vildagliptin as the small effect of weight loss did not account 
for the change in liver triglyceride content. The fall in liver triglyceride content is highly 
unlikely to be secondary to improvement in glycaemic control, as it is not seen during 
therapy with other oral hypoglycaemic agents (Tiikkainen et al., 2004; Phielix et al., 
2013).  
Although previous work (Lim et al., 2011a) demonstrated an association between a 
reduction in hepatic triglyceride content and normalization of fasting HPG, this study 
did not observe this association. The result of this work was consistent with previous 
observations during both vildagliptin and sitagliptin therapy (Azuma et al., 2008; Solis-
Herrera et al., 2013). The lack of improvement in fasting HGP may relate to the very 
well controlled type 2 diabetes under study, as HGP in diabetes has been observed to 
decline to non-diabetic levels below a plasma glucose of approximately 8mmol/l 
(DeFronzo et al., 1989). Secondly, it is reasonable to suggest that during fasting, GLP-
1 and GIP concentrations are at a nadir and inhibition of DPP-4 is unlikely to enhance 
an incretin effect. Considering the known basic mechanism of DDP-4 inhibition, the 
extent of postprandial and fasting effects of vildagliptin on overall glycaemic control 
warrant consideration. Additionally, postprandial glucagon concentration fell by 22% 
(p=0.01) in the vildagliptin treated group, but remained unchanged in the placebo 
group. These observations may explain the difference in the effect of DPP-4 inhibition 
on fasting and postprandial HGP. Although postprandial insulin concentration reduced 
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by 26% (p=0.001), there was no change in the fasting insulin concentration in the 
vildagliptin group.  
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7.6 Future research questions  
The work in this thesis adds to the understanding of type 2 diabetes, and describes 
previously unknown mechanism of action of DPP-4 inhibitors. However, further 
questions arose from the conclusions drawn. The questions posed by observing 
smaller and involuted pancreas in type 2 diabetes are yet to be answered. The question 
of whether or not the smaller, involuted pancreas is secondary to the lack of post-
prandial insulin excursion could be answered by examining the effect of reversal of 
type 2 diabetes on pancreas volume.  
The failure of skeletal muscle to store food carbohydrate and contribute to maintaining 
postprandial glucose haemostasis has been identified as playing a role in the initiation 
of the twin cycle hypothesis of type 2 diabetes. Although vildagliptin did not show any 
improvement in muscle glycogen storage, it is important to investigate the effect of 
other therapeutic option such as high intensity training on muscle glycogen storage in 
type 2 diabetes. Further research questions arising from this work are: 
 
 Can pancreas volume be restored if type 2 diabetes is reversed and normal 
insulin secretion is restored? 
 Does a small pancreas in subjects with strong family history of type 2 diabetes 
and gestational diabetes act as a biomarker for future type 2 diabetes? 
 Can a therapeutic intervention with high intensity training in type 2 diabetes 
improve muscle glycogen storage and postprandial hyperglycaemia? 
 Does vildagliptin affect postprandial hepatic glucose production as a 
consequence of the decreased liver triglyceride in type 2 diabetes? 
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APPENDIX 
APPENDIX 1: CHANGE IN PLASMA GLUCOSE, INSULIN AND 6' 6' - 
DIDEUTERATED GLUCOSE ENRICHMENTS DURING THE CLAMPS 
 
Changes in plasma glucose, insulin and 6' 6' - dideuterated glucose enrichments 
during clamps for vildagliptin treated group 
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Supplemental Figure 1:
Change in plasma glucose, plasma insulin and 6'6'diduterated glucose
enrichment during the clamps - vildagliptin group
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Change in plasma glucose, insulin and 6' 6' - dideuterated glucose enrichments 
during clamps for control group 
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Supplemental Figure 2:
Cha ge in plasma glucose, plasma insulin and 6'6'di uterated glucose
enrichment duri g the clamps - placebo group
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APPENDIX 2: MEAL COMPOSITION FOR CHAPTER 6 - Direct assessment 
of diurnal glycogen storage 
 
BREAKFAST  
Male and female 
 CHO(g) FAT(g) PRO(g) ENERGY 
(kcal) 
Porridge (40g) 33.9 4.8 8.9 365 
banana (200g) 
 
46 0.6 2.2 178 
1 vanilla bean smoothie 
(250mls) 
 
35.25 4.0 10 225 
Tea / Coffee, semi-
skimmed milk 
8.0 3.0 7.0 7.4 
Total 123.15 12.4 28.1 775.4 
 
 
 
 
LUNCH 
Male  
 CHO(g) FAT(g) PRO(g) ENERGY 
(kcal) 
Chicken bacon sandwich 39.8 20.8 24.2 450 
banana (100g) 23 0.3 1.1 89 
2 vanilla bean smoothies 
(500mls) 
 
70.5 8.0 20 450 
Total 133.3 29.1 45.3 989 
 
Female  
 CHO(g) FAT(g) PRO(g) ENERGY 
(kcal) 
chicken stuffing sandwich 44 14 25 400 
banana (100g) 23 0.3 1.1 89 
2 tropical juices (500ml) 25.2 0.2 0.8 110 
Total 92.2 14.5 26.9 599 
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DINNER 
Male  
 CHO(g) FAT(g) PRO(g) ENERGY 
(kcal) 
Beef lasagne 55.6 33.6 30.4 660 
banana (100g) 23 0.3 1.1 89 
1 banana smoothie 
(250mls) 
41.5 0.3 6.5 200 
Total 120.1 34.2 38.0 949 
 
Female 
 CHO(g) FAT(g) PRO(g) ENERGY 
(kcal) 
Spaghetti bolognaise 
 
41.2 28.8 32 560 
banana (100g) 
 
23 0.3 1.1 89 
1 vanilla bean smoothie 
(250mls) 
 
35.25 4.0 10 225 
Total 99.45 33.1 43.1 874 
Carbohydrate (CHO), fat, protein (Pro); energy 
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